IE873149L - Unsaturated phosphonic acids - Google Patents
Unsaturated phosphonic acidsInfo
- Publication number
- IE873149L IE873149L IE873149A IE314987A IE873149L IE 873149 L IE873149 L IE 873149L IE 873149 A IE873149 A IE 873149A IE 314987 A IE314987 A IE 314987A IE 873149 L IE873149 L IE 873149L
- Authority
- IE
- Ireland
- Prior art keywords
- compounds
- formula
- compound
- acid
- substituted
- Prior art date
Links
- 150000003009 phosphonic acids Chemical class 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 135
- 150000003839 salts Chemical class 0.000 claims abstract description 51
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 40
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 19
- 239000005557 antagonist Substances 0.000 claims abstract description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 9
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 8
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphonic acid group Chemical group P(O)(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims abstract description 6
- 125000004450 alkenylene group Chemical group 0.000 claims abstract description 5
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 4
- -1 1,3-propenylene Chemical group 0.000 claims description 60
- 239000000203 mixture Substances 0.000 claims description 48
- 239000002253 acid Substances 0.000 claims description 39
- 238000000034 method Methods 0.000 claims description 37
- 229910052739 hydrogen Inorganic materials 0.000 claims description 29
- 239000001257 hydrogen Substances 0.000 claims description 28
- 230000008569 process Effects 0.000 claims description 22
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 19
- 150000002431 hydrogen Chemical class 0.000 claims description 19
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 claims description 16
- 229910052736 halogen Inorganic materials 0.000 claims description 15
- 150000002367 halogens Chemical class 0.000 claims description 14
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 8
- 125000006239 protecting group Chemical group 0.000 claims description 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 7
- 150000007522 mineralic acids Chemical class 0.000 claims description 7
- 230000003287 optical effect Effects 0.000 claims description 7
- 125000000524 functional group Chemical group 0.000 claims description 6
- 150000002576 ketones Chemical class 0.000 claims description 6
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 5
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 5
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 3
- MBKDYNNUVRNNRF-UHFFFAOYSA-N medronic acid Chemical class OP(O)(=O)CP(O)(O)=O MBKDYNNUVRNNRF-UHFFFAOYSA-N 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 2
- 125000005605 benzo group Chemical group 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 230000002452 interceptive effect Effects 0.000 claims description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims description 2
- 150000003007 phosphonic acid derivatives Chemical class 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 5
- 101100369961 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) erv-1 gene Proteins 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract description 32
- 241000124008 Mammalia Species 0.000 abstract description 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 8
- 230000002378 acidificating effect Effects 0.000 abstract description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract description 2
- 125000002837 carbocyclic group Chemical group 0.000 abstract description 2
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 99
- 239000000243 solution Substances 0.000 description 96
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 78
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 66
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 56
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 49
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 40
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 38
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 34
- 229940093499 ethyl acetate Drugs 0.000 description 33
- 235000019439 ethyl acetate Nutrition 0.000 description 33
- 238000003818 flash chromatography Methods 0.000 description 31
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 18
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 16
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 16
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 16
- 229910052938 sodium sulfate Inorganic materials 0.000 description 16
- 235000011152 sodium sulphate Nutrition 0.000 description 16
- 239000007858 starting material Substances 0.000 description 15
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 14
- 229960000583 acetic acid Drugs 0.000 description 13
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 150000001299 aldehydes Chemical class 0.000 description 11
- 238000009833 condensation Methods 0.000 description 11
- 230000005494 condensation Effects 0.000 description 11
- 229920006395 saturated elastomer Polymers 0.000 description 11
- 206010010904 Convulsion Diseases 0.000 description 10
- 102000018899 Glutamate Receptors Human genes 0.000 description 10
- 108010027915 Glutamate Receptors Proteins 0.000 description 10
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 10
- 239000002585 base Substances 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 8
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 7
- 229960004373 acetylcholine Drugs 0.000 description 7
- 150000007513 acids Chemical class 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 229910021529 ammonia Inorganic materials 0.000 description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 201000006474 Brain Ischemia Diseases 0.000 description 6
- 206010008120 Cerebral ischaemia Diseases 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 206010008118 cerebral infarction Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 230000007062 hydrolysis Effects 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 208000028867 ischemia Diseases 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 208000019901 Anxiety disease Diseases 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 5
- 230000036506 anxiety Effects 0.000 description 5
- 150000007942 carboxylates Chemical class 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 5
- XCXJLWLQQPJVDR-UHFFFAOYSA-N 3-(azepan-2-yl)quinoline Chemical compound C1CCCCNC1C1=CN=C(C=CC=C2)C2=C1 XCXJLWLQQPJVDR-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000012442 inert solvent Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Inorganic materials [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- BDZBKCUKTQZUTL-UHFFFAOYSA-N triethyl phosphite Chemical compound CCOP(OCC)OCC BDZBKCUKTQZUTL-UHFFFAOYSA-N 0.000 description 4
- 229940086542 triethylamine Drugs 0.000 description 4
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 3
- FFNVQNRYTPFDDP-UHFFFAOYSA-N 2-cyanopyridine Chemical compound N#CC1=CC=CC=N1 FFNVQNRYTPFDDP-UHFFFAOYSA-N 0.000 description 3
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 125000005907 alkyl ester group Chemical group 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001640 fractional crystallisation Methods 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 125000004970 halomethyl group Chemical group 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 3
- HXEACLLIILLPRG-UHFFFAOYSA-N pipecolic acid Chemical compound OC(=O)C1CCCCN1 HXEACLLIILLPRG-UHFFFAOYSA-N 0.000 description 3
- 229910003446 platinum oxide Inorganic materials 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 3
- LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 2
- POTIYWUALSJREP-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroquinoline Chemical class N1CCCC2CCCCC21 POTIYWUALSJREP-UHFFFAOYSA-N 0.000 description 2
- CQCAYWAIRTVXIY-UHFFFAOYSA-N 2-(triphenyl-$l^{5}-phosphanylidene)acetaldehyde Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=CC=O)C1=CC=CC=C1 CQCAYWAIRTVXIY-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 238000007239 Wittig reaction Methods 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 150000003973 alkyl amines Chemical class 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000000908 ammonium hydroxide Substances 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 230000001773 anti-convulsant effect Effects 0.000 description 2
- 239000001961 anticonvulsive agent Substances 0.000 description 2
- 229960003965 antiepileptics Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 230000006931 brain damage Effects 0.000 description 2
- 231100000874 brain damage Toxicity 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- KMPWYEUPVWOPIM-KODHJQJWSA-N cinchonidine Chemical compound C1=CC=C2C([C@H]([C@H]3[N@]4CC[C@H]([C@H](C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-KODHJQJWSA-N 0.000 description 2
- KMPWYEUPVWOPIM-UHFFFAOYSA-N cinchonidine Natural products C1=CC=C2C(C(C3N4CCC(C(C4)C=C)C3)O)=CC=NC2=C1 KMPWYEUPVWOPIM-UHFFFAOYSA-N 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 210000001653 corpus striatum Anatomy 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- SOCTUWSJJQCPFX-UHFFFAOYSA-N dichromate(2-) Chemical compound [O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O SOCTUWSJJQCPFX-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 2
- QVLJLWHOILVHJJ-UHFFFAOYSA-N ethyl 2-pyridin-4-ylacetate Chemical compound CCOC(=O)CC1=CC=NC=C1 QVLJLWHOILVHJJ-UHFFFAOYSA-N 0.000 description 2
- 230000002461 excitatory amino acid Effects 0.000 description 2
- 239000003257 excitatory amino acid Substances 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- ODUCDPQEXGNKDN-UHFFFAOYSA-N nitroxyl Chemical group O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-M prolinate Chemical compound [O-]C(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-M 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- 150000003248 quinolines Chemical class 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical class C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 1
- STJWVOQLJPNAQL-UHFFFAOYSA-N 1-[diethoxyphosphorylmethyl(ethoxy)phosphoryl]oxyethane Chemical compound CCOP(=O)(OCC)CP(=O)(OCC)OCC STJWVOQLJPNAQL-UHFFFAOYSA-N 0.000 description 1
- HVOAMIOKNARIMR-UHFFFAOYSA-N 1-pyridin-4-ylethanol Chemical compound CC(O)C1=CC=NC=C1 HVOAMIOKNARIMR-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- PAEXAIBDCHBNDC-UHFFFAOYSA-N 2-pyridin-4-ylacetic acid Chemical compound OC(=O)CC1=CC=NC=C1 PAEXAIBDCHBNDC-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 125000004399 C1-C4 alkenyl group Chemical group 0.000 description 1
- LNKOFJYIQYMCBH-UHFFFAOYSA-N CCOP(=O)OCC.CCP(O)(O)(O)CC Chemical compound CCOP(=O)OCC.CCP(O)(O)(O)CC LNKOFJYIQYMCBH-UHFFFAOYSA-N 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 238000011765 DBA/2 mouse Methods 0.000 description 1
- YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 229940123511 Excitatory amino acid receptor antagonist Drugs 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 241000699684 Meriones unguiculatus Species 0.000 description 1
- 238000005654 Michaelis-Arbuzov synthesis reaction Methods 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- GIIWGCBLYNDKBO-UHFFFAOYSA-N Quinoline 1-oxide Chemical class C1=CC=C2[N+]([O-])=CC=CC2=C1 GIIWGCBLYNDKBO-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- ACIAHEMYLLBZOI-ZZXKWVIFSA-N Unsaturated alcohol Chemical compound CC\C(CO)=C/C ACIAHEMYLLBZOI-ZZXKWVIFSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-M alaninate Chemical compound CC(N)C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-M 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 125000005115 alkyl carbamoyl group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 239000003194 amino acid receptor blocking agent Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000002253 anti-ischaemic effect Effects 0.000 description 1
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 1
- 125000005997 bromomethyl group Chemical group 0.000 description 1
- RRKTZKIUPZVBMF-IBTVXLQLSA-N brucine Chemical compound O([C@@H]1[C@H]([C@H]2C3)[C@@H]4N(C(C1)=O)C=1C=C(C(=CC=11)OC)OC)CC=C2CN2[C@@H]3[C@]41CC2 RRKTZKIUPZVBMF-IBTVXLQLSA-N 0.000 description 1
- RRKTZKIUPZVBMF-UHFFFAOYSA-N brucine Natural products C1=2C=C(OC)C(OC)=CC=2N(C(C2)=O)C3C(C4C5)C2OCC=C4CN2C5C31CC2 RRKTZKIUPZVBMF-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical class C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- LADPCMZCENPFGV-UHFFFAOYSA-N chloromethoxymethylbenzene Chemical class ClCOCC1=CC=CC=C1 LADPCMZCENPFGV-UHFFFAOYSA-N 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 208000012601 choreatic disease Diseases 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940117975 chromium trioxide Drugs 0.000 description 1
- WGLPBDUCMAPZCE-UHFFFAOYSA-N chromium trioxide Inorganic materials O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 1
- GAMDZJFZMJECOS-UHFFFAOYSA-N chromium(6+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Cr+6] GAMDZJFZMJECOS-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000019628 coolness Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 229940079919 digestives enzyme preparation Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- SGAPKKQPDRIYBH-UHFFFAOYSA-N ethyl 4-(2-hydroxyethyl)pyridine-2-carboxylate Chemical compound CCOC(=O)C1=CC(CCO)=CC=N1 SGAPKKQPDRIYBH-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 150000004692 metal hydroxides Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000003431 oxalo group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000005949 ozonolysis reaction Methods 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000006410 propenylene group Chemical group 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- PTMBWNZJOQBTBK-UHFFFAOYSA-N pyridin-4-ylmethanol Chemical compound OCC1=CC=NC=C1 PTMBWNZJOQBTBK-UHFFFAOYSA-N 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- WDXARTMCIRVMAE-UHFFFAOYSA-N quinoline-2-carbonitrile Chemical class C1=CC=CC2=NC(C#N)=CC=C21 WDXARTMCIRVMAE-UHFFFAOYSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 229910001494 silver tetrafluoroborate Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- CRWJEUDFKNYSBX-UHFFFAOYSA-N sodium;hypobromite Chemical compound [Na+].Br[O-] CRWJEUDFKNYSBX-UHFFFAOYSA-N 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- QMGVPVSNSZLJIA-FVWCLLPLSA-N strychnine Chemical class O([C@H]1CC(N([C@H]2[C@H]1[C@H]1C3)C=4C5=CC=CC=4)=O)CC=C1CN1[C@@H]3[C@]25CC1 QMGVPVSNSZLJIA-FVWCLLPLSA-N 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- OCVDGJYRLBEGKG-UHFFFAOYSA-N tert-butyl-dimethyl-[2-(1-oxidopyridin-1-ium-4-yl)ethoxy]silane Chemical compound CC(C)(C)[Si](C)(C)OCCC1=CC=[N+]([O-])C=C1 OCVDGJYRLBEGKG-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000004853 tetrahydropyridinyl group Chemical class N1(CCCC=C1)* 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 208000028325 tonic-clonic seizure Diseases 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- CMSYDJVRTHCWFP-UHFFFAOYSA-N triphenylphosphane;hydrobromide Chemical compound Br.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 CMSYDJVRTHCWFP-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/12—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with only hydrogen atoms attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/60—Quinoline or hydrogenated quinoline ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/59—Hydrogenated pyridine rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Quinoline Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Dental Preparations (AREA)
Abstract
Compounds of the formula I <IMAGE> in which one or both of the acidic hydroxyl groups of the phosphonic acid part can be etherified, m is one or zero, R<1> denotes carboxyl, esterified carboxyl or amidated carboxyl, the heterocyclic five- or six-membered ring can additionally be substituted on the carbon and/or nitrogen, can have a carbon-carbon double bond or can be condensed with a carbocyclic 6-membered ring, starting from adjacent carbon atoms, A represents lower alkenylene; and salts thereof. These compounds are suitable as antagonists of the N-methyl-D-aspartate- sensitive amino acid stimulant receptor in mammals.
Description
° r ^ A W W w "T 2 The present invention is concerned with the compounds of formula I, H®t—A—^ OR ' ( J- ) 1st—A—^ OR ' in which Het is a 2-R1~pyrrolidinyl, 2~R3-™2,5-dihydro-5 pyrrolvlp 2™R1~1,2,3,6-tetrahydropyridinyl» 2-R1-!,2,5,6~ tetrahydropyridinylf 2-R3--piperidinyl, 2-R1-tetrahydro-quinolinyl, 2 =R1 - per hy dr oqu i r? o 1 i ny 1, 2-R1-2, 3-dihydro-indolyl or 2-R^-perhydroindolyl group which also may be M-substituted by C1«-C4alkyl, phenyl~Ci -Chalky1, C2" 10 C7alkoxycarbonyl, benzyloxycarbonyl or by C2~C7alkanoyl and/or C-substituted in the heterocyclic 5- or 5-ring by C1-C4al!-cyl or by phenyl-Ci-C4alkyl and/or, in the fused benzo or cyclohexano radical that may b© present, by C^-C4alkyl, C1-C4alkoxy/ halogen or by trifluorouethyl, R1 15 is carboxy, C1-C4alkoxycarbonyl, carbamoyl or N-mono- or N,N~di-C^-c4alkylcarbamoyl, h is C2~C4alkenylene and R and R' are each independently hydrogen, C1-C4alkyl, benzyl t„ benzyl substituted in the phenyl moiety by halogen,, by Ci-C4alkyl or by C^-C^alkojq/^ C2-C7alkanoyl-20 oxymethyl, or Cj-Cyalkanoyloxymethyl substituted in the oxymethyl noiety by C^-C^alkyl or by C3~C8cycloalkyl ; and salts thereof™ These compounds are suitable as antagonists of the M-methyl-D-aspartate-sensitive excitatory amino acid receptor in mammals. 25 The present invention is further concerned with processes for preparing said compounds, with pharmaceutical compositions comprising said compounds, with processes for the manufacture of such pharmaceutical compositions and with the use of the compounds according to the 30 invention for the preparation of medicaments for treating conditions and diseases in mammals responsive to the effect of an excitatory amino acid receptor antagonist. 3 The compounds of the invention are active and useful in mammals as selective antagonists of the N-methyl-D~ aspartate (MMDA) sensitive excitatory amino acid receptor. The compounds of the invention are therefore 5 also useful, administered alone or in combination to mammals, for the treatment of disorders responsive to a blockade of the MMDA receptor, e.g. cerebral ischemia„ muscular spasms (spasticity), convulsive disorders (epilepsy) and anxiety. The compounds of the invention 10 are also considered effective in the treatment of Huntington1" s disease (Chorea hereditiva)* Fusion originating from adjacent carbon atoms with a six™ membered carbocyclic ring is fusion with e.g. cyclohexyl or phenyl such that the fused heterocyclic ring in 15 formula I is represented by a bicyclic ring system containing 9 or 10 ring-forming atoms,, depending on the value of the symbol a in formula I.
A preferred arrangement of the invention relates to compounds of the formula II />/-i ' (in ! °S Nji x and compounds of formula II with a double bond present between C-3 and c-4 or between C-4 and C~5 of the piperidinyl ring, wherein R and R' are each independently hydrogen,, Ci-C4&lkylt, benzyl, benzyl substituted in the 25 phenyl moiety by halogen,, by C^-C/jalkyl or by Ci-C4- alkoxy,, C2-C7alkanoyloxymethyl, or C2-C7aIkanoy 1 oxymethyl substituted in the oxymethyl moiety by C1-C4alkyl or by C3-Cacycl°alkyl, R1 is carboxy, Ci-C4alkoxycarbonyl, carbamoyl or N-mono- or N,N-di~C1-C4alkylcarbamoyl, R2 is 4 hydrogen, C1-C4alkyl, phenyl-C1-C4alkyl, C2-C7alkoxy= carbony1c ben2y1oxycarbony1 or C2~C7alkanoyl, R3 is hydrogen, c1~c4alkyl or phenyl-C1-C4alkyl, and A is C2-C4alkenyl@ne; and salts thereof. 5 Preferred are the compounds of formula II wherein R and R# are each independently hydrogen,, C1-C4alkyl, benssyl, C2~C7a1kanoy1oxyxne thy]. or C2-C7alksnoyloxymethyl substituted in the oxymethyl moiety by C^-C^alkyl, by cyclohexyl or by cvclopentyl, H1 is carboxy, carbamoyl or 10 C1-C4alkoxycarbonyl; R2 and R3 are hydrogen or Ci- C4alkyl, and A is alkenylene having from 2 to 4 carbon atomsand pharmaceutically acceptable salts thereof,, Further preferred are the compounds of formula II wherein R and R'? are each independently hydrogen, Co-15 C7alkanoyloxymethyl or C^-C^alkanoyloxyssethyl substituted in the oxymethyl moiety by C^-C^alkyl, R1 is carboxy,, carbamoyl or Ci-C4alkoxycarbonyl, B2 and R3 are hydrogen P and A is in the 4-position, and is alkenylene having 3 or 4 carbon atoms with the double bond adjacent to the 20 phosphono group; and pharmaceutically acceptable salts thereof.
Particularly preferred are the compounds of formula III Yv wherein A is 1,3-propenylene, preferably with the double 25 bond adjacent to the phosphono group, and R1 is carboxy or Ci-C4alkoxycarbonyl; and pharmaceutically acceptable salts thereof.
A preferred arrangement concerns the compounds of formula 5 III wherein the 2- and 4-substituents are cis to each other.
Another aspect of the invention relates to compounds of formula iv m A—OR' R'* —i- H i vyv (iv) i2 or perhydro derivatives thereof f wherein R and Rf are each independently hydrogenf, Ci--C4alkyl, benzyl, benzyl substituted ir# the phenyl moiety by halogen,, by Cj-C4alkyl or by C1-C4alkoxy, C2-C7alkanoyloxymethyl, or C2-10 C7alkanoyloxysiethyl substituted in the oxymethyl moiety by C1-c4alkyl or by C3~Cgcycloaikyl, R3- is carboxy, Ci_-C4alkoxycarbonyl, carbamoyl or N-mono~ or M^IP-di-Ci-C4alkylcarbaMoylc R2 is hydrogen, Cx-C4alkyl, phenyl-Cj-C4alkyl, C1-C7alkoxycarbonyl, benzyloxycarbonyl or C2~ 15 C7alkanoyl, R4 is hydrogen, Cx-C4alkyl, Ci-C4alkoxy, halogen or trifluorossethyl, and A is C2-C4alkenylene; and salts thereof.
Preferred are the compounds of formula ¥ (V) 20 or perhydroquinoline derivatives thereof, wherein A is 1,3-propenylene with the double bond adjacent to the phosphono group , and R~ is carboxy or Cx-C4alkoxy~ carbonyl; and pharmaceutically acceptable salts of said compounds having a salt-forming functional group. 6 Most preferred are the compounds of formula v wherein the 2- and 4~substituents are cis to each other.
A further aspect of the invention relates to compounds of formula VI R3—+ 4—A—P—OR ° 5 "y\i L I2 and the compounds of formula VI with a double bond present between C-3 and C-4 of the pyrrolidine1 ring, wherein R and R** are each independently hydrogen, Ci_-C4alkyl, benzyl, benzyl substituted in the phenyl moiety 10 by halogen, by -Chalky1 or by Ci-C4alJcoxy, C2-C7- alkanoyloxymethyl, or C^-C^alkanoyloxyaiethyl substituted in the oxymethyl moiety by Ci~C4alkyl or by C3~CQcycl©~ alkyl, R1 is carboxy, Cj-^alkoxycarbonyl, carbamoyl or M-aaono- or N,N-di-Cx-C4alkylcarbamoyl, R2 is hydrogen, 15 Cx-C4alkyl, Ci-Cyalkoxycarbonyl, benzyloxycarbonyl or €3-Cyalkanoyl, R3 is hydrogen, C1-C4alkyl or aryl-Ci-C4alkyl, and A is C2~C4alkenylene; and salts thereof.
Preferred are the compounds of formula VI wherein the phosphono-bearing group is attached at the 3-position? R 20 snd a* are hydrogen, R1 is carboxy or Ci -C4alk©3cy~ carbonyl, R2 and R3 are hydrogen,, and A is 1,3-propenyl- ene with the double borsd adjacent to the phosphono group? and pharmaceutically acceptable salts thereof.
The general definitions used herein have the following 25 Meaning in the context of the invention.
The term "lower" when used hereinbefore and hereinafter in connection with organic groups, radicals or compounds. 7 defines such groups, radicals or compounds having up to and including 7, preferably up to and including 4 and advantageously one, two or three carbon atoms„ C1-C4alkyl is, for example, ethyl, propyl, butyl or 5 advantageously methyl.
Cj-^alkenylene representing A denotes, for example, ethenylene, 1,3-propenylene, 1,4-but~l-enylene, 1,4-but-2-e.nylene, advantageously with the double bond adjacent to the phosphono grouping. 10 C1-C4alkoxy represents, for example, ethoxy, propoxy or advantageously methoxy.
C2~C7alkanoyl advantageously represents acetyl, propion-yl , n-butyryl, isobutyryl or pivaloyl, but may also be formyl- 15 C2~Cya1karsoy1oxy advantageously represents acetoxy, propionyloxy, n- or i-toutyryloxy or pivaloyloxy.
C3-Cgcycloalkyl represents, for example, cyclohexyl or cyclopentyl.
Halogen is preferably fluorine or chlorine., taut aiay also 20 represent bromine or iodine.
Phenyl-Ci -^alkyl advantageously represents benzyl or 2-phenethyl.
Ci-C7alkoxycarbonyl preferably contains 1 to 4 carbon atoms in the alkoxy moiety and represents,, for example, 25 methoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl or advantageously ethoxycarbonvl.
H M-C1-C4alkylcarbam°yl is, for example, N-methylcarbamoyl, N-propylcarbamoyl or advantageously N-ethylcarbamoyl.
N^N-di-Cx-C^alkylcarbamoyl represents, for example, N,N-dimethylcarbaiaoyl, N-ethyl-N-aethylcarbamoyl and advant-5 ageously N,N-diethylcarbamoyl.
Salts of the compounds of the invention are preferably pharmaceutically acceptable salts , on the one hand metal or ammonium salts of the compounds of the invention having a free phosphono or carboxy group, more par-10 ticularly alkali or alkaline earth metal salts, e.g. sodium, potassium, magnesium or calcium salts," or advantageously crystallising araraoniu® salts derived from ammonia or organic amines^ such as methylaaine, diethyl-amine, triethylaaine, dicyclohexylaaine, triethanolaaine, 15 ethylenediamine, tris-(hydroxymethy1)aainoaethane or benzyltrimethylaaaoniua hydroxide. On the other hand the compounds of the invention which are basic amines fora acid addition salts with preferably pharmaceutically acceptable inorganic or organic acids, such as strong 20 mineral acids, for example hydrohalic acids, e.g. hydrochloric or hydrobroaic acid; sulfuric, phosphoric or nitric acid; aliphatic or aromatic carboxylic or sulfonic acids, e.g. acetic, propionic, succinic, glycolic, lactic, aalic, tartaric, gluconic, citric, 25 ascorbic, maleic, fuaaric, pyruvic, paaoic, nicotinic aethanesulfonic, ethanesulfonic, hydroxyeth&nesulfonic, benzenesulfonic, p-toluenesulfonic or naphthalenesulfonic acid.
Salts that are not suitable for pharmaceutical purposes 30 mey be obtained for isolation or purification purposes. However,, only pharmaceutically acceptable salts are used for therapeutic purposes and these salts, therefore, are preferred. 8 The compounds of the invention exhibit valuable pharmacological properties, e.g. selective blocking of the N-methyl-D-aspartate~s@nsitive excitatory amino acid receptors in mammals. The compounds are thus suitable 5 for treating diseases responsive to the blocking of excitatory amino acid in mammals,, e.g. nervous system disorders„ particularly convulsive disorders (epilepsy) and anxiety.
These effects can be demonstrated in in vitro tests or in vivo animal tests advantageously using mammals or tissues or enzyme preparations thereof,, e.g., mica, rats or monkeys. The said compounds can be administered enterally or parenterally, advantageously orally or transdermal ly, or subcutaneous ly,, intravenously or intra-peritoneally, for example,, within gelatin capsules, or in the form of aqueous suspension or solutions. The in vivo dosage administered may range between about Q.oi to 100 ®g/kg (3 preferably between about 0.05 and 50 mg/kg, advantageously between about 0.1 ©nd 10 Eg/kg. The said compounds can be administered jjj vitro in the form of e.g. aqueous solutions for which the dosage may range jjk 0 between about 10 "* solar and 10 molar concentrations.
The inhibitory effect on the HHDA-type excitatory amino acid receptors is determined in vitro by Measuring the 25 inhibition of NMD&-induced ^■-acetylcholine (3H-kCh) release from corpus striatum tissue of rat brain„ according to J. Lehasann and B. Scatton, Brain Research 252, 77-89 (198,2) and Mature 297 , 422-424 (1982) .
Antagonists of NHDA-type excitatory amino acid receptors 30 competitvely antagonize NMDA-induced 3H-acetylcholine (3H-ACh) release from corpus striatum tissue of the brain. 10 15 20 ■1 0 The inhibition of MMDA-induced ^-acetylcholine (3H—ACh) release from rat striatal tissue slices by a. compound of the invention is expressed as a percentage of the release of 3H-ACh in response to stimulation with 5 50 juM NMDA compared with a. control test™ Tests are two-tailed with a minimum of n = 4 in each group. IC50 values represent the concentration of test compound required to inhibit by 50 % the 3H~ACh release increased by NMDA. 1© The inhibitory effect on the NMDA-type excitatory amino acid receptors is demonstrated in vivo by inhibition of NMDA-induced convulsions in mice.
Representative compounds of the invention prevent NMDA-induced convulsions in mice at doses down to about 15 1-2 nig/kg i. p.
A further indication of the anticonvulsant activity is that compounds of tile invention are effective in preventing audiogenically induced seizures in DBA/2 Mice [Chapman mi-, Ar2neim--Forsch. 34; 1261, (1984)]. 20 2-Aaaino- -phosphonoalkenoic acids and functional derivatives thereof having NMDA-antagonistic properties are known from GB-A-2104079. The compounds prepared in accordance with the invention differ from those compounds by the structural feature of the heterocyclic group Hefc 25 in place of the ^CH-NH2 group- The activity is determined as follows: Forty five minutes following compound or vehicle administration, mice are placed individually in a soundproof chamber- After a 30 second accommodation period, the mice are 30 exposed to a sound stimulation of 110 dB for 1 minute or 1 1 until the appearance of a tonic-clonic seizure. Control seizures consist of an initial wild running phase. The prevention of wild running is indicative of an anticonvulsant activity.
Test compounds in either distilled water solution or in a 3 % colloidal cornstarch suspension containing 5 % by weight polyethyleneglycol 400 and 0.34 % Tween 80, are administered orally or intraperitoneally in a volume of 10 ml/kg body weight.
An indication of anxiolytic activity is the fact that the compounds of the invention are effective in the Cook/Davidson conflict model [Psychopharmacologia 15 „ 159-168 (1969)].
The cerebral antiischemic activity,, that is the effect of the compounds of the invention in preventing or reducing brain damage in mammals caused by a transient, cerebral ischemia (as in a stroke), can be determined in the mongolian gerbil ischemia model, e.g. the model described by T. Xirino in Brain Research 239, 57-69 (1982).
The inhibitory effect on the observed hyperactivity and on the degeneration of neurons in the hippocampus region of the brain following a 5-minute period of ischemia is measured. The test compound is administered i.p. 15 minutes before the ischemia or 2,, 4 and S hours post ischemia.
Representative compounds of the invention, administered at a dose of 10 mg/kg i.p. either before or after the ischemia episode, inhibit the ischemia-induced hyperactivity of the gerbil and reduce the degeneration of cerebral neurons as measured in the hippocampus region of 1 the brain.
The aforementioned advantageous properties render the compounds of the invention useful as antagonists of the N-methyl-D-aspartate-sensitive excitatory amino acid 5 receptor in mammals and for the treatment of conditions responsive thereto, such as anxiety and convulsive disorders.
The compounds of the invention, i.e. the compounds cited hereinabove,, may be prepared by conventional processes, 10 e.g. by a) condensing an aldehyde or ketone of formula vn Het-A' (vii) wherein Het and R1 are as defined for formula I but R1 and amino groups ar© in protected form, and A' is Ci« 15 C3alkyl substituted by oxo and containing one carbon atom less than the alkenylene group A, with a tetraaster derivative of methylenediphosphonic acid under basic conditions and, if required, removing protecting groups from the resulting product to obtain a compound of 20 formula I wherein the double bond within group A is directly adjacent to the phosphono group; or b) condensing a compound of formula VIII Het-A-X (VIII) wherein Met,,, A and R1 ar© as defined for formula I and 1 25 is reactive esterified hydroxy, with a compound capable of introducing the phosphonic acid moiety and having one of the formulae II and X «J .8 .i H—I—OR" (IX) ?(R"') 3 (X) 1r" wherein Rm is C^-^alkyl and R'*S! is halogen or Ci_-C4aXkoxy snd, if required, converting the resulting phosphonic acid derivative to the phosphorsic acid or 5 another ester derivative thereof; or c) converting to R1 a substituent other than R1 at position 2 of the heterocyclic ring in a compound otherwise identical to a compound of the invention; and carrying out the said processes with, if necessary,, 10 temporary protection of any interfering reactive groups,, and then freeing the resulting compound of the invention; if desired converting a resulting compound of the invention into another compound of the invention and/or, if desired j, converting a resulting free compound into a 15 salt or a resulting salt into the free compound or into another salt? and/or separating a mixture of isomers or of racemates into the individual isomers or racemates; and/or, if desired, resolving a racemate into the optical antipodes. 20 Reactive esterified hydroxy, in any of the herein-mentioned processes, e„g» X in a compound of formula viii, is esterified by a strong acid, especially a hydrohalic acid, e.g. hydrochloric, hydrobromic or hvdriodic acid, or sulfuric acid, or by a strong organic 25 acid, especially a strong organic sulfonic acid, such as an aliphatic or aromatic sulfonic acid, for example methanesulfonic acid, 4-nethylphenylsulfonic acid or 4-bromophenylsulfonic ©c.id„ The said reactive esterified hydroxy is especially halosulfonyioxy, for example 30 chloro-, broaso- or iodo-sulfonyloxy, or aliphatically or aromatically substituted sulfonyloxy, for example f 1 Jb -jj methanesulfonyloxy, phenylsulfonyloxy or 4-methylphenyl-sulfonyloxy (tosy1oxy).
In starting compounds and intermediates which are converted to the compounds of the invention in the manner 5 described herein,, functional groups present, such as carboxy„ amino (including ring MH) and hydroxy groups, are therefore optionally protected by conventional protecting groups that are common in preparative organic chemistry. Protected carboxy, amino and hydroxy groups 10 are those that can be converted under mild conditions into free carboxy, amino and hydroxy groups without the molecular framework being destroyed or other undesired side reactions taking place.
The purpose of introducing protecting groups is to 15 protect the functional groups from undesired reactions with reaction components and under the conditions used for carrying out ©. desired chemical transformation. The need and choice of protecting groups for a particular reaction is known to those skilled, in the art and depends 20 on the nature of the functional groups to be protected (carboxy group, amino group, etc.), the structure and stability of the molecule of which the substituent is a part and the reaction conditions.
Well-known protecting groups that meet these conditions 25 and their introduction and removal are described,, for example, in J.F.W. McOmiet, "Protective Groups in Organic Chemistry", Plenum Press, London, Mew York 1973, T.W. Greene, "Protective Groups in Organic Synthesis", Wiley, New York 1981, and also in "The Peptides", Vol.I, 30 Schroeder and Luebka,,, Academic Press, London, Mew York 1965, as well as in Houben-Weyl, "Hethoden der Organischen Chemie", Vol. 15/1, Georg Thieme Verlag, Stuttgart, 1974.
The preparation of the compounds of the invention wherein the double bond is adjacent to the phosphono grouping according to process (a) involving the condensation of an aldehyde or ketone with e.g. a lower alkyl ester of methylenediphosphonic acid is carried out according to processes known in the art for such condensations, in the presence of a strong anhydrous basee.g. butyl-lithium, in an inert polar solvent such as tetrahydro~ furan, preferably under reflux The starting aldehydes or ketones of formula VII can be prepared e.g., by oxidation of the corresponding alcohols, for example with pyridin-ium chlorochrornate, or by other methods, e.g. as illustrated in the Examples.
The respective alcohols can in turn b® prepared by methods that are known per gfi, e.g. by reduction of the corresponding aromatic alcohols using methods known in the art for the reduction of pyrrole, pyridine, indole and quinoline compounds. For example, the reduction of the pyridine or quinoline ring is preferably carried out with an organometal1ic reducing agent or by catalytic hydrogenation, e.g. in the presence of platinum oxide and an acidic solvent, such as acetic acid, to give car-responding tetrahydropyridines, piperidines, 1,2,3,4-tetrahydroquinolines or perhydroquinolines of the invention, e.g. according to formula II or IV and derivatives thereof. Quaternary guinoliniua and pyridin-iu» compounds, e.g. those in which Eg is lower alkyl or aryl-lower alkyl, may be similarly reduced.
The alcohols, aldehydes or ketones so obtained may also be converted to aldehydes or ketones of longer chain length using conventional processes, e.g. by a wittig condensation of an aldehyde with methoxy-methy1 -triphenylphosphonium chloride to yield the homologous ■ 1 6 aldehyde, and by other reaction sequences known per sa. e.g. as described in the Examples.
The aromatic 2~carboxy~heterocyclyl~substituted lower alkanols referred to above, for example the 2-carboxy-5 pyridinyl- or 2-carboxy-auino1iny1-substi tuted lower alkanols or derivatives thereof, can in turn be prepared by treatment of the 2-unsubstituted pyridinyl-substituted or 2-unsuhst.ituted quinolinyl-substituted lower alkanols in suitably protected form, with e.g. a peracid, such as 10 m-chloroperbenzoic acid, to give the corresponding pyridine-N~oxides or quinoline-N-oxides. Condensation with a reactive cyanide, e.g. a trialkylsilyl cyanide such as trimethylsilyl cyanide, preferably under basic conditions, e.g. in the presence of triethylamine, gives 15 the corresponding 2~cyanopyridine or 2-cyanoquinoline derivatives which ©re then converted, again in a sanner known per se., to the 2-R1 (carboxy, esterified or amidated carboxy)-substituted pyridine and quinoline derivatives. 20 The condensation according to process (b) is advantageously used for the preparation of the compounds of forxaula 1 wherein, the double bond within the alJcenylene grouping & is not directly adjacent to the phosphono grouping. 25 The condensation according to process (b) of a compound of formula vixi with a compound of formula X, e„g„ triethyl phosphite, is carried out,, e.g. toy heating in an inert solvent, and under conditions that are known for a. Michaelis-Arbuzov reaction according to 30 Angew. Chem. Int. Ed. 16. 477 (1977) and Chem. Rev. 81,3 415 (1981). Similarly? condensation with e.g. phosphorus trichloride and subsequent hydrolysis gives a compound of formula I.
The condensation according to process (b) of a compound of formula VIII with a compound of formula IX„ e.g. diethylphosphonate (diethyl phosphite), is carried out e.g. in a strong basic medium, for instance in the presence of an alkali metal, e.g. sodium, an alkali metal hydrides, e.g. sodium hydride, an alkali metal alkoxides e.g. potassium t-butoxide5 in an inert solvent e.g. toluene or diraethylformamide.
The starting materials of formula VIII and reactive derivatives thereof can be prepared by methods well known in the art starting from intermediates of formula VII wherein A' represents oxo-substi-tuted lower alkyle the preparation of which is described above.
For example, the starting material of formula VIII wherein A represents propenylene is prepared by condensing an aldehyde of formula VII, wherein the grouping A9 represents formyl (CH~0), with a suitable Wit tig reagent, e.g. formylmethylene-triphenylphosphoran® ,s reducing the resulting unsaturated aldehyde (in which the chain has been lengthened by two carbon atoms) to the alcohol e.g. with sodium borohydride, and converting the resulting unsaturated alcohol to a reactive derivative, e.g. the bromide with triphenylphosphine/M-bromo-succinimide.
Interconversions according to process (c) are carried out by methods well-known in the art.
Groups convertible into R1 ares for example, carboxy groups inthe form of anhydrides or acid ha1ides„ eyano, amidino groups, including cyclic araidino groups such as 5-tetrazolyl» iminoether groups, including cyclic iminoether groups,, e.g. dihydro-2-oxasoliny 1 or dihydro-2-ojtazolinyl groups substituted by lower alkyl, and also hydroxymethyi„ etherified hydroxyiaethyls lower aIkanoyloxymethyl, I B trialkoxyraethyl, acetyl,, trihaloacetyl, halomethyl, carboxy carbonyl (COCOOH)s, formyl (CHO), di( lower)alkoxytnethvl, alkylenedioxymethyl or vinyl.
Certain terms used in the processes have the meanings as defined 5 below.
Oxo-substituted lower alkyl represents preferably formyl„ formyl-snethyl9 formylethyl or 2-oxo-propy 1, Trialkoxytnethyl represents preferably cri(lower alkoxy)methyl, particularly triethoxv- or trimethoxymethyl. 10 Etherified hydroxyraethyl represents preferably lower alkoxvmethy1, lower alkoxyalkoxymethyl, e.g. methoxymethoxymethyl or 2-oxa~ or 2-thiacyclo-alkoxymethyl, particularly 2~tetrahydropyranyloxy~ methyl.
Halomethyl represents especially chloromethyl but may also be 15 bromomethyl or iodomethyl.
An alkali metal represents preferably lithium but may also be potassium or sodium.
Groups convertible into R1 representing carboxy include esterified and amidated carboxy and such are not limited to esterified and 20 amidated carboxy as defined herein for R'. Conversion to carboxy is generally accomplished by solvolysis, with acid or base.
Benzyloxycarbonyl or nitrobenzyloxycarbonyl may be converted into carboxy by catalytic hvdrogenation„ the latter also with chemical reducing agents, e.g. sodium dithionite or with zinc and a carboxy-25 lie acid. In addition^ tart-butyloxycarbonyl may also be cleaved with trifluoroacetic acid. 1 9 Acetyl niay be oxidacively cleaved to carboxy by conversion £irst to trihaloacetyl, e.g. tribrosno or triiodoacetvl, by treatment e.g. with sodium hypobromite, followed by cleavage with e.g. an aqueous base, e.g. sodium hydroxide.
Formyl, di( lower)-alkoxyraethyl or alkylenedioxymethyl (formyl protected in the form of an acetal), e.g. the dimethyl acetal, are oxidized with e.g. silver nitrate, pyridiniura dichromate or ozone to carboxy.
Vinyl may be converted to carboxy by ozonolysis to formyl, which is in turn oxidized to carboxy.
Hydrolysis of trialkoxymethyl to carboxy is advantageously carried out with inorganic acids, e.g. hydrohalic or sulfuric acid. Hydrolysis of etherified hydroxvaiethyl to hydroxyraethyl is preferably carried out with solutions of inorganic acids, e.g. a hydrohalic acido Hydroxymethyl is in turn oxidized to carboxy with an oxidizing agent, eg, pyridiniura dichromate.
Halomethyl may also be converted to the corresponding carboxalde-hydes with e.g. dimethylsulfoxide in the presence of triethylamine and silver tetrafluoroborate, or with chromium trioxide and pyridine in dichloromethane.
The conversion of cyano to lower aIkoxycarbonyl is advantageously carried out by treatment first with a lower alkanol, e.g. anhydrous ethanolj, in the presence of a strong acid, e.g. hydrochloric acid preferably at reflux temperature„ followed by hydrolysis with water.
Furthermore,, the conversion of cyano to carbamoyl is preferably carried out by treatment with an alkali metal hydroxide, e.g. dilute sodium hydroxide, and hydrogen peroxide, preferably at room terape- 2 0 Esterified carboxy such as lower aIkoxycarbonyl raay be amidated with ammonia, mono- or di~(lower)alkylamines, e.g. methylamine, dimethylamine, in an inert solvent, e.g. a lower alkanolf such as butanol, to unsubstituted, 5 mono- or di~(lower)alkylcarbamoyl.
The compounds of the invention may thus also be converted to other compounds of the invention e.g. by functional group conversions well-known in the art.
For example, conversion of carboxylie acid esters and 10 amides to carboxylie acids is advantageously carried out by hydrolysis with inorganic acids such as a hydrohalic or sulfuric acid or with aqueous alkalis, preferably alkali metal hydroxides such as lithium or sodium hydroxide. 15 Free carboxylic acids may be esterified with lower alkanols, such as ethanol, in the presence of a strong acid,, e.g. sulfuric acid, or with diazo (lower) alkanes, e.g. diazomethane, in a solvent such as ethyl ether, advantageously at room temperature,, to give the cor-20 responding lower alkyl esters.
Furthermore, the free carboxylic acids may be converted by treatment of a reactive derivative thereof, e.g. an acyl halide such as the acid chloride, or a mixed anhydride, e.g. one derived from a lo*»er alkyl halo-25 carbonate such as ethyl chlorocarbonate, with ammonia, mono- or di- (lower) alkylamines, in an inert solvent such as dichloromethane, preferably in the presence of a basic catalyst such as pyridine, to compounds wherein RA o 4 x represents unsubstituted, mono- or di-(lower)&lkyl~ carbamoyl.
Phosphor?,ic acid, esters are converted to the corresponding phosphonic acids by treatment with acid, such as aqueous 5 hydrochloric acid or hydrobromic acid in glacial acetic acid, or with bromotrimethylsilane according to J. Chen. Soc. Chem. Coram* 1979. 739. Benzyl esters may be converted to the acids by hydrogenolysis.
Phosphonic acids are converted to esters,, e.g. optionally 10 substituted lower alkyl esters, e„g» by condensation with an optionally substituted lower alkyl halide preferably in a basic non-aqueous -medium, such as in the presence of triethylamine.
In a preferred embodiment of the invention a compound of 15 formula I wherein Ket is N-substituted by C^-C^-alkanoyl or by C2-C7&lkoxycarbonyl, R and R* are Cr-C4alky 1, benzyl, bensyl substituted in the phenyl moiety by-halogen, by Ci-C4alkyl or by -C4alkoxy, C2~C7alkanoyl-oxymethyl, or C2-C7a 1 kanoy 1 oxymetry 1 substituted in the 20 oxymethyl moiety by Ci-C^alkyl or by C3-Cgcycloalkyl, and R1 is C1-C4alkoxycarbonyl, carbamoyl or N-mono- or N,N-di-C1-C4alkylcarbonyl, is converted into a corresponding N-unsubstituted compound of formula I in which R and R' are hydrogen and R3- is carboxy f by treatment with an 25 inorganic acid or with aqueous alkalis, there being suitable as inorganc acids hydrohalic acid or sulfuric acid, especially hydrochloric acid, and, as aqueous alkalis, alkali metal hydroxides, especially lithium or sodium hydroxide, preferably at elevated temperature. •> •> The above-mentioned reactions are carried out according to standard methods,, in the presence or absence of diluents,, preferably those that are inert to the reac-tants and are solvents therefor, of catalysts, of 5 condensing or said other agents and/or in an inert atmosphere, at low temperatures, room temperature or elevated temperatures, preferably ©t the boiling point of the solvents used, and at atmospheric or super-atmospheric pressure. The preferred solvents, catalysts and 10 reaction conditions are set forth in the following i1lustrative Examples.
The invention further includes any variant of the present processes in which an intermediate product obtainable at any stage thereof is used as starting material and the 15 remaining steps are carried out, or the process is discontinued at, any stage thereof,, or in which the starting materials are formed under the reaction conditions, or in which the reactants are used in the form of their salts or pur® antipodes.
Mainly those starting materials should be used in said reactions, that lead to the formation of those compounds indicated above as being especially preferred.
The invention also relates to any novel starting materials and processes for their manufacture.
Depending on the choice of starting saaterials and methods, the new compounds may be in the form of one of the possible isomers or mixtures thereof9 for example, depending on the number of asymmetric carbon atoms, as pure optical isomers, such as antipodes, or as mixtures of optical isomers such as racernates or as mixtures of diastereoisomers or of geometric isomers- The aforesaid possible isomers esidmixtures thereof are within the scope of this invention; certain particular isomers are preferred as indicated above.
Any resulting mixtures of diastereoisomersormixtures of racernates can be separated on the basis of the physicochemical differences of the constituents9 in known manner, into the pure isomers, diastereoisomers j, racernates, or geometric isomers, for example by chromatography and/or fractional crystallization.
Any resulting racernates can be resolved into the optical antipodes by known methods, for example by reacting en acidic end produc with an optically active base that forms salts with the raceaic acid, and separating the salts obtained in this manner, for example by fractional crystallization, into the diastereoisomeric salts from which the optically active free carboxylic or phosphonic acid antipodes can be liberated on acidification. The basic racemic products can likewise be resolved into the optical antipodes, e.g. by separation of the diastereoisomeric salts thereof, with an optically active acid,, and liberating the optically active basic compound by treatment with a standard base. Racemic products of the invention can thus be resolved into their optical antipodes, e.g., by the fractional crystallisation of d- or £-(tartrates, mandelates. 2 4 camphor sulfonates) or of d- or-jKcs-raethylbenzylamine, cinchonidine, cinchonine, quinine, quinidine, ephedrine, dehydroabietylamina, brucine or strychnine) salts. The acidic compounds of the invention can also be resolved by separating diastereomeric ester or amide derivatives prepared from an optically active alcohol or amine, and freeing the separated optically active compound. Advantageously,, the more active of the two antipodes is isolated.
Finally the compounds of the invention are obtained either in the free forai or as salts.. Any resulting base can be converted into a corresponding acid addition salt, preferably with the use of a therapeutically acceptable acid csranion exchange preparation, or resulting salts can be converted into the corresponding free bases, for example with the use of a stronger base, such as a metal or ammonium hydroxide or a basic salts, ® • g • an alkali metal hydroxide or carbonate, or a cation exchange preparation, or an alkylene oxide such as propylene oxide. A compound of the invention with a free carboxylic or phosphonic acid group can thus also be converted into the corresponding metal or ammonium salts. These or other salts, for exasaple9 the picrates5 can also be used for purification of th® bases obtained; the bases are converted into salts, the salts are separated and the bases are liberated from the salts.
In view of the close relationship beween the free compounds and the compounds in the forsa of their salts,, whenever a compound is referred to in this contexts ® corresponding salt is also McLudadL, provided such is possible or appropriate under the circumstances.
The compounds, including their salts, can also be obtained in the form of their hydrates, or include other solvents used for their crystallization.
The pharmaceutical compositions according to the invention are those suitable for enteral, such as oral or rectal, transdermal and parenteral administration to mammals, including man, for blocking the N-methyl-D-aspartate«sensitive excitatory amino acid receptor and for the treatment of diseases responsive to the blocking of the M-methyl-D-aspartate->sensitive excitatory amino acid receptor, such as cerebral ischemia, convulsive disorders and anxiety, comprising an effective amount of a pharmacologically active compound of the invention, alone or in combination with one or more pharmaceutical^ acceptable carriers„ The pharmacologically active compounds of the invention are useful in the manufacture of pharmaceutical compositions comprising an effective amount thereof in conjunction or admixture with carriers suitable for either enteral or parenteral application. Preferred are tablets and gelatin capsules comprising the active ingredient together with a) diluents, e.g. lactose, dextrose, sucrose,, raannitol. sorbitol, cellulose and/or glycine* b) lubricants, e.g. silicas talcum, stearic acid, its magnesium or calcium salts and/or polyethyleneglycol; for tablets also c) binders e.g. magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium cErboxymethyIcellulose and/or polyvinylpyrrolidone? if desired d) disintegrants, e.g. starches, agar, alginic acid or its sodium salt, or effervescent mixtures; and/or e) absorbents, colorants, flavors and sweeteners. Injectable compositions are preferably aqueous isotonic solutions or suspensions 5 and suppositories are advantageously prepared from fatty emulsions or suspensions. Said compositions may be sterilized and/or contain adjuvants, such as preserving, stabilising, wetting or emulsifying agentss solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances. Said compositions are prepared according to conventional sizing3 granulating or coating methods, and contain about 0„ 1 to 73 preferably about 1 to 50 %. of the active ingredient.
Suitable formulations for transdermal application include an effective amount of a compound of formula I *»ith carrier. Advantageous carriers include absorbable pharmacologically acceptable solvents to assist passage through the skin of the host. Characte- 2 G risCically, transdermal systems are in the form of a bandage comprising aprotective layer» a reservoir containing the compound optionally with carriers, optionally a rate—controlling means to deliver the compound to the skin of the host at a controlled and predetermined rate over a prolonged period of time, and means to secure the device to the skin.
The invention also relates to a method of blocking the N-methyl-D-aspartate—sensitive excitatory amino acid receptor in mammals, and to a" method of treatment of disorders in mammals, e.g.those responsive tto the bLocking of the N-methyl-D-aspartate excitatory amino acid receptor, such as cerebral ischemia, convulsive disorders and anxiety, using an effective amount of a compound of the invention as a pharmacologically active substance, preferably in the form of above-cited pharmaceutical compositions.
A particular embodiment thereof relates to a method of treating cerebral ischemia and of inhibiting brain damage resulting from cerebral ischemia (in a stroke) in mammals which comprises EdrairxLsear"-i&o; to a nannal in need o:t sactj. tx* A unit dosage for a mammal of about 50 to 70 kg may contain between about 5 and 100 sng of the active ingredient.
The following examples are intended to illustrate the invention and are not to be construed as being limitations thereof. Temperatures are given in degrees Centigrade. If not mentioned otherwise, all evaporations ©re performed under reduced pressure, preferably between about 2 and 13 kPa.
Example 1: Ethyl 4-[ l-( 3-diethylphosphonoprop-*-2-enyl) ]-l»tert~ butoxycarbonylpiperidina-2-carboxylata is hvdrolyzed with 6N hydrochloric acid to yield 4-[1~(3-phosphonoprop-2--enyl)]piperidine-2-carboxylic acid.
The starting material is prepared as follows; &-(2-hydroxyethyl)-pyridine is oxidized to 4-(2-hydroxyethyl)"pyridine-M~oxide which is in turn treated with trimethylsilyl cyanide to yield 4-(2-hydroxy-ethy1)-2-cyanopyridine which is converted to ethyl 4-(2-hydroxy~ ethyl)=2~pyridine carboxylate and then hydrogenated to yield ethyl 4-(2-hydroxyethy1)-piperidine-2-carboxylate.
A solution of 2=01 g of ethyl 4-(2-hydroxyethy1)-piperidine-2-carboxylate in 5 ml dichlororaethane is added to a solution of 2.20 g of di-tert-butyl dicarbonate in 10 ml dichloromethane. After standing for 10 minutes the solvent is evaporated and the residue is flash chromatographed with hexane/ethyl acetate ( "j z 1 ) to afford ethyl 4-(2-hydroxyethy1)-1-tart-butoxycarbonylpiperidine-2-carboxylate .
To a solution of 1.56 g of dimethyl sulfoxide in 10 ml dichloromethane is added 2.2 g of oxalyl chloride at ~78°C» After 20 minutes 2.4 g of ethyl 4~(2-hydroxyethyl)-I-tert-butoxycarbonyi--piperidina-2-carboxylata in 5 sal dichloromethane is added. The reaction Haxijurs is stirred for one hour and 2.2 g of triathylamine is add®d. The ice bath is removed, the solvent evaporated and the residue is flash chromatographed with hexane/ethyl acetate (7 s 3} co afford l-fcert-butoxycarbonvlpiperidine-2-© tnoxy carbonyl ->U—6ice-s®J.dehyde„ At -78°C„ 2.73 ml n-butyllithium is added to 2.02 g bis(diethyl~ phosphono)-methane in 20 ml anhydrous tetrahvdrofuran. After 5 minutes 2.08 g of 1 — tert—butoxycarfoonylpipesaLdine—2-e£fro:>sycar-» banyi-4-acetaldehyde in 5 ml tetrahydrofuran is added. The mixture is then refluxed for 16 hours. The cooled reaction mixture is concan- trated and flash chromatographed (95:5 dichlorosnethane/methanol) to yield ethyl 4~[l-(3~diethylphosphonoprop-2-enyl) ]-l-tert-butoxy-carbony1piperidine-2-carboxylate.
Example 2: The following compounds can be prepared according to methods generally illustrated in the previous examples (a) trans 3-( !-( 4-phosphonobut-3-enyl) ]-pyrrolidine-2~carboxylic acid; (b) trans 3-[l-(4-phosphonobut-2-enyl)]=pyrrolidine-2-carboxylie acid.
The starting material for compound (a) can be prepared as follows; Trans N-e thosycayboxiylpyrx-olidi:o.e~2—e thoxycarbonyl->»3~&ca^2Llde-» hyde is condensed with (C&Hs)3?=CHOCH3 under conditions of th® yittig reaction to afford trans N ~ Chcscyce^rbcaiylpyrroJidLn.e ~ 2— ethoEy~ carbonyl-3-propionaldehyde. Condensation with bis-(diethyiphos-phono)methane under conditions described herein (see Example 1) yields trans ethyl 3-[ l-(4-diethylphosphonobut-3-enyl) ]-pyrrolid.ine- 2-carboxylate.
The starting material for compound (b) can be prepared as follows: The alcohol9 trans ethyl N»ethoxycarbonyl--3-( 2-hydroxyethyl)-pyrrolidine-2-carboxylate is oxidized to the aldehyde „ trans M— © thoxy carbonyl pyr rol idirte -2 — @thoxycarbanyl-3~&ce t&ldehyd%*itjichj3 condensed with triphenylphosphoranylideneacetaldehyde under conditions of the Wittig reaction; the resulting et,^^unsaturated -aldehyde is reduced to the corresponding alcohol which is converted to the bromide. Condensation with triethyl phosphite yields ethyl 3-(l-(4-diethylphosphonobut-2-enyl)]-pyrrolldine-2-carboxylase.
Example 3° 4-»[1~(3-Phosphonoprop-l-enyl)]piperidine-2~carboxylic acid can be similarly prepared using ethyl 4-hydroxymethy1-K-ethoxycarbonyl- 30 piperidina-2-carboxylate as intermediate. 10 15 20 25 2 9-' Example 4; At ■=-78°C, 20.3 ml of butyllithium (1.64 M) is added to 8.5 ml of tetraethylmethylenediphosphonate (bis(diethylphosphono)-methane] in 100 ml anhydrous tetrahydrofuran. After 5 minutes. 9.26 g of 1 -(tex:t-butoxycarbonyl)-2-ethoxycarbonyl-piperidine-4-acetaldehyde in 125 ml anhydrous tetrahydrofuran is added. Mixture is refluxed 18 hours, cooled„ concentrated and purified by flash chromatography using ethyl acetate/hexane (75:25 to 9:1) to yield ethyl 4-[ l-( 3-diethylphosphonoprop-2-eny1)]-(1-tert-butoxycarbonyl)-piperidine-2-carboxylate.
The starting material is prepared as follows: A solution of 4-pyridylacetic acid in 500 ml of anhydrous ethanol containing 75 ml of concentrated sulfuric acid is refluxed 18 hours. The solution is cooled to 0°C and neutralized by addition of sodium hydroxide solution and saturated aqueous sodium carbonate. Extraction with ethyl acetate yields on concentration in vacuo ethyl 4-pyridyl-acetate.
A solution of 23.8 g of ethyl 4-pyridylacetate in 100 ml of anhydrous tetrahydrofuran is added dropwise to 5.5 g of lithium aluminum hydride in 150 ml of anhydrous tetrahydrofuran under nitrogen. The mixture is heated at 50°C (bath) for 40 minutes? then cooled in an ice bath, and the excess lithium aluminum hydride is decomposed by additiosi of 6.6 ml of water followed by 6.6 ml of 15 % aqueous sodium hydroxide and 20 ml of water. The solid is filtered off and the filtrate concentrated in vacuo to yield 4-pyridy1-ethanol.
A solution of 16.3 g of 4-pyridvlethanol, 21.8 g of chloro-terebut yl-dimet hyl si lana and 10.9 g of imidazole in 150 sal of dimethyl-formamide is stirred 1 hour at room temperature. The product is isolated by extraction in ethyl acetate/hexane (1:1) and washed 4 times with 400 ml of water; the extract is filtered through silica gel and concentrated in vacuo to yield 4-(tert-butyl-dimathylsilyl-oxyethyl)-pyridine . 3 fll To a stirred solution of 28.8 g of 4~(tert-butyl-dimethylsilyloxy-ethyl)-pyridine in 300 ml of dichioromethane is added 24 g of m-chloroperbenzoic acid. After 4 hours the solution is washed with aqueous sodium carbonate solution and water. The solution is dried over sodium sulfate, filtered and concentrated in vacuo to yield 4-(tert-butyl-dimethylsilyloxyethyl)-pyridine-N-oxide.
A solution of 28.6 g of 4-(tert-butyl-diiaethylsilyloxyethyl)-pyridine-N-oxide, 60.3 ml of trimethylsilyl cyanide and 31.5 ml triethylainine is stirred under nitrogen at reflux for 3 hours. The dark solution is cooled in an ice bath. 30 ml of ethanol added;, followed by 400 ml ethyl acetate and 200 ml hexane. The solution is washed twice, with 150 ml of water, dried over sodium sulfate, filtered, concentrated in vacuo and purified by flash chromatography using ethyl acetate/hexane (1:10) to yield 4-(tert-butyl-diiaethyi-silyloxyethyl)-2--cyanopyridine» A solution of 22.2 g of 4-( tert-butyi-=dimethylsilyloxyethyl)~2-cyanopyridine in 220 ml anhydrous ethanol containing 0.19 g of sodium is stirred at room temperature for 24 hours. The solution is then cooled to 0°C and 22 ml of 6N hydrochloric acid added. The solution is stirred at room temperature for 16 hourss cooled to 0°C and 7.5 ml 6N sodium hydroxide added followed by 75 mi saturated aqueous sodium bicarbonate. Extraction with dichioromethane and flash chromatography using ethyl acetate yields ethyl 4-(2-hydroxy™ ethyl)-pyridine-2-carboxylate.
A mixture of 8.37 g of ethyl 4-(2-hydroxyethyl)-pyridine-2-carboxylate in 130 ml acetic acid and 4 g platinum oxide is hydro-genated at 345 kPa. Filtration, concentration in vacuo, neutralization with potassium carbonate and extraction with dichioromethane yields an oil that is purified by flash chromatography using dichioromethane/methanol saturated with ammonia (20:1) to yield ethyl 4-(2-hydroxyethy!)-piperidina-2-carboxylate. 3 1 A solution of 7.9 g of ethyl-4-(2-hydroxysthy1)-piperldine-2-carboxylate, 9.0 g di~tert-butyl dicarbonate in 80 ml of dichioromethane is stirred for 2 hours at room temperature and then concentrated in vacuo to yield ethyl l-(tert-butoxycarbonyl)-4-(2-hydroxy-5 ethyl)-piperidine-2-carboxylate.
A solution of 11.8 g of ethyl(l-tert-butoxycarbonyl)-4~(2"hydroxy-ethyl)-piperidine-2-carboxylate and 12.6 g of pyridinium chloro-chromate in 175 sal dichioromethane is stirred under nitrogen at room temperature for 80 minutes. Mixture is filtered and purified by 10 flash chromatography using ethyl acetate/hexane (25;75) to yield l-(tert-buto xyc ar bony 1)-2-e thoxy car bony 1-piperidine-4-ace'c aldehyde.
Example 5; A mixture of 4.67 g of ethyl 4-[l-(3-diethylphosphono-prop-2-enyl]-l-(tert-butoxycarbonyl)-~piperidine-2-carboxylate and 75 ml 6M hydrochloric acid is refluxed 12 hours. The solution is •j 5 concentrated in vacuo to dryness. The residue is taken up in 50 ml ethanol and 3.8 ml of propylene oxide added. The solid that separates is filtered off and dried in vacuo to yield cis-4-[ ].-(3-phosphonoprop-2-enyl) ]-piperidine-2-carboxylic acids ra.p. 1S3-165°C.
Example 6; At ~78°Ca 5.9 snl of butyllithium (1.6 M) is added to 2.9 sal of tetraethylmethylene diphosphonate in 30 ml anhydrous tetrahydrofuran. After 5 minutes, 2„&7 g of trans 1 —acetyIpipsr-±d±ne~2—eftioaeyc&rboayl~li™&o&tgi]dehyde in 55"2- of anhydrous tstra™ hydrafur&jj. is added. The mixture is refluxed 18 hours, cooled, concentrated and purified by flash chromatography using dichloro-aethane/ethanol (100:3) to yield trans ethyl 4-[l-(3-diethylphos-phonoprop-2-enyl) 3~i~acetyl~piperidine-2-carboxylate.
The starting raaterial is prepared as follows: At 0°C? 9.4 ml acetic anhydride is added to a stirred solution of 13.5 g of ethyl 4~( 2-hydroxyethyI)-piperidine-2-carboxylate in 75 ml pyridine. After 30 stirring at room temperature for 30 minutes the solution is concentrated in vacuo and ethyl acetate (300 ®1) is added; the solution is washed twice vith 2M hydrochloric acid;, once with water and once 20 25 with saturated sodium bicarbonate, dried over sodiura sulfate, filtered and concentrated in vacuo. The residue is taken up in 100 ml ethanol, S g of powdered potassium carbonate is added and the mixture stirred 1 hour at room temperature. The solution is filtered, concentrated in vacuo and purified by flash chromatography using dichioromethane/methanol (95:5) to yield trans ethyl 1 — ece tyl—k- (2~hydroxy0 thyl) —piperidine~2~carbo3:ylate.
A mixture of 3.7 g of trans ethyl l-acetyl-4-(2-hydroxyethyl)-piperidina-2-carboxylate and 5.4 g of pyridinium chlorochromate in 75 ml dichioromethane is stirred under nitrogen for 2 hours. The mixture is filtered and purified by flash chromatography using ethyl acetate/hexane (7:3 to 8; 2) to yield trans 1 ~ace tyl pi peri dine—2 ~ a thos:ycarbonyl«L;.-acs teldehyde Example 7; A mixture of 2.5 g of trans ethyl 4-[l-(3-diethylphos-phonoprop~2-enyl)]~l-acetylpiperidine-2-carboxylate and 40 ml 6N hydrochloric acid is refluxed for 12 hours. Th© solution is concentrated in vacuo to dryness. The residue is taken up in 20 ml of ethanol and 2.3 ml of propylene oxide added. The solid that separates is filtered off and dried in vacuo to yield trans 4-(l-(3-phosphonoprop-2-euyl)]-piperidine-2-carboxylie acid, ra.p. 132-140°C- Example 8; A solution of 0.334 g of trans ethyl 4-fl-(3-bromoprop-l~ enyl) ]-J.-(tart-butoxycarbonyl)~pip®ridine~2-carboxyl&te and 3.5 ml of triethylphosphit® is refluxed under nitrogen for 70 minutes. The cooled solution is concentrated in vacuo and purified by flash chromatography using dichlorotnethana/methanol (100;3) to yield trans ethyl 4~(X~(3-diethylphosphonoprop-l-enyl)]-l~(tert-butoxycarbonyl)~ pi peridine-2~carboxylase.
The starting material is prepared as follows; A solution of 20 g 4-pyridvlcarbinol, 28.9 g of chloro-tert-butyl-diraethylsilan® and 14.4 g imidazole in 200 ml disaathylforraasaide is stirred 3 hours at room temperature. Product is isolated by extraction in ethyl **3^ ' m"y tjjft acetate/hexane (Is!) and the extract is cashed h tirres witii lujonl of water. The solution is filtered through silica gel and concentrated in vacuo to yield 4-(tert-butyl-dimathylsilvloxymethyl)-pyridine.
A solution of 40.6 g of 4-(eert-butyl-dimethy1silyloxyraethyl)-pyridine and 40 g of m-chloroperbenzoic acid in 500 ml dichioromethane is stirred 16 hours at room temperature. Solution is washed with 2M sodium hydroxide and water, dried over sodium sulfate, filtered and concentrated in vacuo to yield 4~(tert-butvldimethyl-silyloxyicnethyl)~pyridine~N-*oxide.
A solution of 37„9 g of 4-(tert-butyl-dimethylsilyloxymethyl)-pyridine-M-oxide, 84 ml of trimethyIsilyl cyanide and 44 ml tri-ethylamine is stirred under nitrogen at reflux for 2 1/2 hours. Dark solution is cooled in an ice bacht then 40 ml of ethanol added followed by 500 ml of ethyl acetate. The solution is washed twice with waters dried over sodium sulfates filtered9 concentrated in vacuo and purified by flash chromatography using ethyl acetate/hexane (Is 10) to yield 4-(tert-butyl-diraethylsilvloxy-aathyi)-2-cyanopyridine.
A solution of 21.7 g of 4-(tert-butyl-dimethylsilyloxymethyl)-2~ cyanopyridine in 220 ml anhydrous ethanol containing 0.2 g of sodium is stirred at room temperature for 18 hours, cooled to 0°C and 22 al 6N hydrochloric acid is then added. The solution is stirred at room temperature for 18 hours,, cooled to 0°C8 7.5 ml SN sodium hydroxide added followed by 20 ml saturated aqueous sodium carbonate. Extraction with dichioromethane, then drying, filtering and concentrating the extract yields an oil which crystallizes from ether to yield ethyl 4-(hydroxymethyl)-pyridine-2~carboxylate. a mixture of 13.9 g of ethyl a-(hydroxymethyl)~pyridine-=2-carfooxy-lates 5 g platinum oxide in 250 ml acetic acid is hydrogenated at 34h kPa. Filtration, concentration in vacuo, and neutralisation with potassium carbonate in dichioromethane yields an oil is «> >s £ -dl purified by flash chromatography using dichlororaethane/snethanol saturated with ammonia (20:1) to yield ethyl 4-(hydroxymethyl)-piperidine-2-carboxylata.
A solution of 5.16 g of ethyl 4-(hydroxymethyl)-piperidine-2-5 carboxylate and 6.33 g di-tert-butyl dicarbonate in 100 ml of dichioromethane is stirred at room temperature for 18 hours. The solution is concentrated in vacuo to yield ethyl l-(tert-butoxy-carbony1)-4-(hydroxyraethyl)-piperidine-2-carboxylate.
A solution of 7.9 g of ethyl 1™(tert-butoxycarbonyl)-4~(hydroxys 10 methyl)-piperidine-2-carboxylate and 9.9 g of pyridinium chloro- chromate in 175 ml of dichioromethane is stirred at room temperature for 3 hours. The mixture is filtered and purified by flash chromatography using ethyl acetate/hexane (25?75) to yield l-(tert-butoxy-carbony!)-2-ethoxvcarbonylpiperidine-4-carboxaldehyde- A solution of 1 g of l-( tert-butojcycarbonyl)-2=ethoxycarbony 1-piperidina-4~casboxaldshyde and 2 g of forraylmethylene-triphenyl-phosphoran irs 16 ml of toluene is heated to 100°C (bath temp« ) lbr 2 hours. The solution is cooled and purified by flash chromatography using ethyl acetate/hexane (25?75) to yield X-(tert-butoxycarbonyl)-2-eehoxycarbonyl--piperidine-4™scrylaldehyde. h solution of 0.83 g of l-(tesT-butojcycarbonyl)-2-ethoxycarbonyI~ piperidi«®-4-acryialdehyde and 0.11 g of sodium borohydride in 8 ml of ethanol is stirred at 0°C for 30 minutes; 0.2 ml of acetic acid is added followed by ice cold water and the mixture is extracted 25 with dichioromethane. The extract is dried over sodium sulfates filtered and concentrated in vacuo. Purification by flash chromatography using ethylacetate/hexane (25s75) yields trans ethyl l-(tert-butoxycarbonvl)-4-[l-(3-hydroxyprop-I-enyl)]-piperidine-2~carboxy™ late. 15 20 try o b A solution of 0.367 g of trans ethyl 1 - (tert-butoxycarbonyl)-4-[i-(3-hydroxyprop-I-enyl)]-piperidine~2~carboxylate , 0.35 g triphenyl-phosphin® and 0.23 g of bromosuccinimide in 8 ml of dichioromethane is stirred initially at 0°C and then at room temperature for 40 minutes. Purification by flash chromatography using ethyl acetate/hexane (1:9) yields trans ethyl 4-{l-(3-bromoprop-l-enyl) ]-1~(tert-butoxycarbony1)-piperidine-2-carboxylate.
Example 9; A solution of 0.39 g of trans ethyl 4-[l-(3-diethvlphos-phonoprop-l-enyl) ]-l-( tert-butoxvcarbonyl)-piperidine-2-carboxylate and 2»3 ml of trifluoroacetic acid in 8 ml of dichioromethane is stirred at room temperature for 30 minutes. Saturated aqueous sodium bicarbonate is added and the mixture extracted with dichioromethane. Purification by flash chromatography using dichioromethane/methanol saturated with ammonia (20;!) yields trans ethyl 4-[l-(3-diethyl-phosphonoprop-l-enyl)]-piperidine-2-carboxy late.
Example 10; A solution of 0.265 g of trans ethyl 4-[1~(3-diethyl-phosphonoprop-l-enyl) ]-pipe xridine-2-car boxy late in 5 ml of anhydrous ethanol containing 0.074 ml of butyl lithium (1.6 M) is heated at &D°C (bath tempi') for 72 hours. After coolings 0.025 ml acetic acid is addeds followed by excess saturated sodium bicarbonate, and the mixture is extracted with dichioromethane. The dichioromethane extract on concentration in vacuo yields an oil; purification by flash chromatography using dichlororaethane/isopropanol saturated with ammonia (20:1) yields cis ethyl 4-[l-(3~diethylphosphonoprop-X-> enyl)]-piperidine~2~carboxylate.
Example 11; a) A mixture of 0.142 g of cis ethyl 4-[ 1~( 3-diethylphosphonoprop-1-enyl)]-pipsridine-2-carboxylate and 2.5 ml of 6N hydrochloric acid is refluxed for 12 hours. The solution is concentrated in vacuo to dryness. The residue is 'fcaken. up in 2 mi of ethanol and 0.15 tal of propylene oxide is added- The solid that separates is filtered off and dried in vacuo to yield cis «-[ l-( 3~phosphonoprop~X~ex>yl) ]-piperidine~2-carboxylic ®cid9 m.p. 175°C (decomposition)» 3 6 b) Similarly, hydrolysis of the trans ester of Example 9 yields the corresponding trans acid, a.p. 130-135°C. c) A solution of cis &-[l-(3-phosphonoprop-l-enyi)]-piperidine~2-casrboxylie acid in saturated ethanolic hydrochloric acid is heated under reflux overnight. The solvent is removed in vacuo. A solution of the residue in ethanol is treated with propylene oxide and evaporated to dryness to yield cis ethyl 4~[1~(3-phosphonoprop-l-enyl)]-piperidine-2-carboxylate.
Example 12; To a solution of 0.234 g of trans 1-ethoxycarbony1=2-ethoxycarbonyl-pyrrolidine-3-propionaldehyde in 5 ml of anhydrous tetrahydrofuran under nitrogen, cooled to -78°C3 is added slowly a solution of 0.23 ml of tetraethylmethylenediphosphonate and 0.57 sal of butyllithium (1.6 H) in 5 sal of anhydrous tetrahydrofuran also at -78°C, Solution is refluxed for 14 hours, cooled and treated with 0.15 ml of acetic acid; the reaction mixture is concentrated, diluted with water and extracted with dichioromethane. The extract is dried over sodium sulfate, filtered and concentrated9* purification by flash chromatography using ethyl acetate yields trans ethyl l-ethoxvcarbonyl-3-fl-(4-diethylphosphonobut-3-enyl)]-pyrrolidine-2-carboxylate.
The starting material is prepared as follows: A mixture of 50 g of M~(2-cys.noathyl)glycine in 300 sal of ethanol saturated with hydrogen chloride gas is stirred 1 hour at room tesaperatur® then refluxed for 1 hour. After cooling the solid is filtered off and the filtrate neutralised with sodium bicarbonate,, filtered again and concentrated to yield ethyl M-(ethoxycarbonylmethyl)-B-alaninat:e.
To a mixture of 49 g of ethyl !3-(ethoxycarbonyiinethyl)-g™©laninate and 30 ml of water cooled to ~10°C is added dropwise 27.6 s>l of ethyl chlorocssrbooatBfollowed by a solution, of 12.7 g of sodiusa carbonate in 50 ml of water. The mixture is warmed to room tempera-ture then heated at 55°C for 50 minutes. The saixxure is cooled, extracted with toluene6 the extract is washed with 2H hydrochloric 3 7 acid and water. The extract is dried over sodium sulfate, filtered, concentrated and distilled in vacuo to yield ethyl N-(ethoxycar-bonylmethyl)-N-(ethoxycarbonyl)~g~alaninate.
A solution of 53.9 g of ethyl N-(ethoxycarbonylmethyl)-N-(ethoxy-carbonyl)-g-alaninate in 200 ml of toluene is added dropwise to a stirred solution of potassium hexamethyldisilazide (429 ml, 0.653 M) in 125 sal of toluene under nitrogen and cooled to 0°C. After 45 minutes at 0°C, 21.6 sal of acetic acid is added followed by a solution of 100 g of sodium phosphate (monobasic) in 1 liter of water. The phases are separated, the organic phase is washed with pH 7 buffer, dried over sodium sulfate, filtered, concentrated and purified by flash chromatography using ethyl acetate/hexane (3:7) to yield ethyl 1 -e'choxycarbonyl-3-oxo-pyrrolIdine-2-carboxylace.
To a stirred suspension of 24 g of benzyloxycarbonylmeehyl~tri-phenylphosphonium bromide in 225 ml of anhydrous tetrahydrofuran under nitrogen and cooled to 0°C is added 73 ml of potassium hexamethyldisilazide (0.652 M). After 10 minutes a solution of 11 g of ethyl l~ethoxycarbonyl-3-oxopyrrolidine-2~carboxylate in 50 ml of tetrahydrofuran is added and the mixture refluxed 2 1/2 hours. After cooling the mixture is filtered and concentrated in vacuo. The residue is dissolved in ethyl acetate, washed with water, dried over sodium sulfate, filtered, concentrated and purified by flash chromatography using ethyl acetate/hexane (1:4) to yield an oil;; this is hydrogenated in 200 ml of ethanol and 5 g of 10 % palladium on carbon to yield9 after filtering and concentrating the filtrate, l~ethoxycarbonyl~2--ethoxycarbonylpyrrolidine-3~acetic acid.
A solution of 10 g of l-ethoxycarbonyl--2~ethoxvcarbonyl-pyrrolidine-3~acetic acid in 50 ml tetrahydrofuran is cooled to 0°C and 55 ml of borane/tetrahydrofuran (1 M) is added dropwise. After stirring 2 hours at 0°CS 20 ml of water is added, the mixture is extracted with ethyl acetate® washed twice with water and dried over sodium sulfate. The solution is filtered, concentrated and purified by 3 8 flash chromatography using ethyl acetate/hexane (1:1 to 7:3) to yield cis 1-ethoxycarbonyl~2-echoxycarbonylpyrrolidine~3-ethanol.
A solution of 6 g of cis 1-ethoxycarbony1-2-ethoxycarbonyl-pyrrolidine-3-ethanol in 75 ml of dichioromethane containing 7.3 ml of diisopropylethylamine, to which is added 5.1 ml of 85 % benzyl-oxymethyl chlorides is stirred 3 1/2 hours at room temperature. The solution is washed with water and saturated aqueous sodium bicarbonate. The solution is then dried over sodium sulfate, filtered, concentrated and purified by flash chromatography using ethyl acetate/hexane (1:4) to yield cis ethyl l-ethoxycarbonyl-3-[2-(benzyloxymethoxy)-ethyl]-pyrrolidine-2-carboxylate.
A solution of 6.2 g of cis ethyl l~ethoxycarbonyl~3~[2-(benzyloxy-raethoxy)-ethyl]-pyrrolidine-2-carboxylate in 75 ml of anhydrous ethanol containing 1 ml of butyllithium (1.6 M) is refluxed under nitrogen for 6 days. After cooling, 1.7 ml of IN hydrochloric acid is added, the solution is concentrated in vacuo, cold water added and mixture extracted with dichioromethane. The extract, is dried over sodium sulfate, filtereds concentrated and purified by high pressure liquid chromatography using ethyl acetate/hexane (15:85) t yield trans ethyl 1~ethoxycarbonyl-3-[ 2=(benzyloxymethoxy)-ethyl ]-pyrrolidine-2-carboxylace.
A mixture of 1.64 g of trans ethyl l-ethoxycarbonyl-3-f(2-benzyi-oxymethoxy)-ethyl]-pyrrolidine-2-carboxylate and 2 g of 10 % palladium on carbon in 35 &1 of acetic acid is hydrogenated at 310 k'Pa. The Mixture is filtered, concentrated in vacuo and purified by flash chromatography using ethyl acetate/hexane (6:4 to 7:3) to yield trans l-ethoxvcarbonyl-2-ethoxycarbonylpyrroli-dine-3-ethanol.
A solution of 0.991 g of trans l-ethoxycarbonyl-2-ethoxycarbonyl-pyrrolidine-3-ethanol and 1.24 g pyridinium chlorochromate in 20 ml of dichioromethane is stirred under nitrogen for 4 hours. Mixture i 39 filtered and purified by flash chromatography using ethyl acetate/hexane (1:1) to yield trans l-ethoxycarbonyl-2-ethoxvcarbo-nyIpyrrolidine-3-acetaldehyde.
To 0.4 g of trans 1-ethoxycarbony1-2-ethoxycarbonylpyrrolidine-3-scetaldehvde in 5 snl anhydrous tetrahydrofuran under nitrogen, cooled to -78°C, is added dropwise a solution of 1.17 g of raethoxy-methyl-triphenylphosphoniura chloride in 15 ml of anhydrous tetrahydrofuran, which contains 1.55 ml of potassium tert-butoxide/tetrahydrofuran (1.6 M), Solution is stirred at room temperature for 4 hours. 2N hydrochloric acid (11 ml) is added and the mixture is stirred for 45 minutes. The solution is concentrated and then extracted with dichioromethane. The extract is dried over sodium sulfate, filtered, concentrated and the residue is purified by flash chromatography using ethyl acetate/hexane (1:5 to 3:7) to yield trans l~ethoxycarbonyl-2~ethoxycarbonylpyrrolidine-3-propionaldehvde.
Example 13: A mixture of 0.193 g of trans ethyl 1-ethoxycarbonyl-3-[ l-(4-diethylphosphonobut~3-enyl) ]~pyrrolidine-2--carboxylate and 4 snl of concentrated hydrochloric acid is refluxed for 16 hours. The solution is cooled and concentrated to dryness in vacuo. The solid that separates is filtered off and dried in vacuo to yield trans 3"[ l-(4-phosphonobut-3-enyl) ]-pyrrolidine-2-carboxylic acid, to.p. 110-115°C (decomposition) Example 14; To a solution of 0.426 g cis l-athoxycarbonvl-2-ethoxy™ car bony lpyrrolidine-3-propi one Idehyde in 10 ml of anhydrous tetrahydrofuran under nitrogen, cooled to -78°C, is added slowly a solution of 0.45 ml of tetraethylmethylenediphosphonate and 1.06 ml of butyl lithium (1.6 M) in 10 ml of anhydrous tetrahydrofuran also at ~78°C. Solution is refluxed 14 hours, cooled and 0.3 si! acetic acid is added; the reaction mixture is concentrated, water is added and the mixture is extracted with dichioromethane. The extract is dried over sodium sulfate, filtered, concentrated and purified by 4"0 flash chromatography using ethyl acetate to yield cis ethyl l-ethoxycarbonyl-3-[l-(4-diethylphosphonobut-3-enyl)]-pyrrolidine-2-carboxylate.
The starting material is prepared as follows: A solution of 0.908 g 5 of cis l-ethoxycarbonyl-2~ethoxycarbonylpyrrolidine~3~ethanol and 1.14 g pyridinium chlorochroiaate in 20 ml of dichioromethane is stirred under nitrogen for 4 hours. Mixture is filtered and purified by flash chromatography using ethyl acetate/hexane (1:1) to yield cis 1-ethoxvcarbonyl-2-ethoxycarbonylpyrrolidine~3-acetaldehyde.
To 0.663 g of cis l-ethoxycarbonyl-2-ethoxycarbonylpyrrolidine-3-acetaldehyde in 10 ml anhydrous tetrahydrofuran under nitrogen, cooled to -78°C„ is added dropwise a solution of 2.21 g of tnethoxy-methyl-triphenvlphosphonium chloride in 20 ail of anhydrous tetrahydrofuran which contains 2.6 sal of potassium tert-butoxide/tetrahydrofuran (1.6 M). Solution is stirred at room temperature for k hours; 15 ml of 2N hydrochloric acid is added and the mixture stirred for 45 minutes. The solution is concentrated and then extracted with dichioromethane. The extract is dried over sodium sulfate„ filtered and concentratedi purification by flash chromatography using ethyl acetate/hexane (1:5 to 3:7) yields cis l~ethoxycarbonyl-2-ethoxycarbonylpyrrolidine-3-propionaidehyde.
Example 15: A mixture of 0.176 g of cis ethyl l-ethoxycarbonyl-3-[1-(4~diethylphosphonobut-3-enyl)]-pyrrolidine~2-carboxylate and 3.5 ml of concentrated hydrochloric acid is refluxed 18 hours. The 25 solution is concentrated in vacuo to dryness, the residue talcsn up in 1.5 al of isopropanol/methanol (5:1) and 0.2 nil of propylene oxide is added. The solid that separates is filtered off and dried in vacuo to yield cis 3-(l-(4-phosphonobut-3-enyl)]-pyrrolidine-2-carboxylic acid, si.p. 132=140°C. 10 15 20 4 I Example 16: A solution of 0=0665 g of trans ethyl 1-ethoxycarbonyl-3-[ l-(4-brotnobut-2-enyl) ]-pyrrolidine-2-carboxylate in 0.75 ral of triethylphosphite is refluxed 20 minutes. The solution is concentrated in vacuo and the residue purified by flash chromatography using dichloromethane/ethanol (30:1) to yield trans ethyl I-ethoxy-carbonyl-3-[1=(4-diethylphosphonobut-2-enyl)]™pyrrolidine~2~carboxy~ late.
The starting material is prepared as follows: A solution of 0.225 g of trans 1-ethoxycarbonv1-2-ethoxycarbonyIpyrro1idine-3-acetaldehyde and 0.4 g of (formyImethyleine)-1riphenylphosphoran in 2 ml of dichioromethane is refluxed 44 hours. The solution is concentrated and the residue is purified by flash chromatography using ethyl acetate/hexane (2:3) to yield trans ethyl l-ethoxycarbonyl~3-*[ l-(4-oxobut~2~enyl)]-pyrrolidine-2-carboxylate.
To a stirred solution of 0.102 g of trans ethyl l-ethoxycarbonyl™3~ (l-(4-oxobut-2-enyl)]-pyrrolidine-2~carboxylats in 2 ral of ethanol cooled to 0°C is added 0.035 g of sodium borohydride. After 30 minutes at 0°C and 30 minutes at room temperature 0.05 ml of acetic acid is added, the solution concentrated, water added and the mixture extracted with dichioromethane. The solution is dried over sodium sulfate, filtered and concentrated in vacuo to yield trans ethyl l-ethoxycarbonvl=3-[l-(4-hydroxybut-2-enyl)]-pyrrolidine-2-carboxylate.
To a stirred solution of 0.0937 g of trans ethyl 1-ethoxycarbonyl-3-[!-(4-hydroxybut~2-enyl)]~pyrrolidine-2-carboxylate and 0.1 g of triphenylphosphine in 2 ml of dichioromethane at 0°C is added 0.067 g of M-bromosuccinisnide• After 30 minutes at room temperature the mixture is purified by flash chromatography using ethyl acetate/hexane (1:3) to yield trans ethyl l-ethoxycarbonyl-3-ll-(4~ bromobut-2-enyl)]-pyrrolidine=2-carboxylate. 4 2 Example 17; A mixture of 0.053 g of trans ethyl 1-ethoxycarbonyl-3-[1-(4~diethylphosphonobut-2-enyl)]-pyrrolidine-2~carboxylate and 1.5 ml of concentrated hydrochloric acid is refluxed for 16 hours. The solution 5 is concentrated to dryness in vacuo, the residue is taken up in 1 ml of methanol, 0.2 ml of propylene oxide is added and the solution is concentrated. The residue is purified by ion exchange chromatography eluting with 0.1M ammonium hydroxide solution to yield trans 3-[l-(4~ 10 phosphonobut-2-enyl) ]-pyrrolidine-2-carboxylie acid,, ra.p. 138-145°C.
Example 18: preparation of an injectable formulation containing 10 mg of the active ingredient per 5 ml of solutions 15 ' cis 4-[l-(3-phospiionoprop~l~enyl) ]- piperidine-2-carboxylic acid 10.0 g propylparaben 0.5 g water ad 5000,0 ml The active ingredient and preservative are dissolved in 20 3500 ml of water for injection purposes and the solution is diluted to 5000 ml. The solution is filtered through a sterile filter and filled into injection ampoules under sterile conditions» each ampoule containing 5 ml of the solution. 25 Example 19s a) Preparation of 10,000 tablets each containing 10 mg of the active ingredients cis 4-[l—(3-phosphonoprop-1-enyl)]~ piperidine~2~carboxylic acid 100.00 g 30 lactose 2,535.00 g cornstarch 125,00 g polyethylene glycol magnesium stearate water (sterile) 6000 150.00 g 40.00 g q.s.
Procedure: All the powders are passed through a sieve with openings of 0.6 mm. Then the active compound, lactose, magnesium stearate and half of the starch are mixed in a suitable mixer. The other half of the starch is suspended in 65 ml of water and the suspension added to a boiling solution of the polyethylene glycol in 260 ml of water. The paste formed is added to the powder mixture,, which if necessary is granulated with additional water. The granulate is dried overnight at 35°C, forced through a sieve with 1.2 mm openings and compressed into concave tablets with upper breaking notches.
Tablets containing about 1-50 mg of one of the other compounds disclosed hereinbefore are prepared in an analogous manner- b) Preparation of 1,000 capsules each containing 5 mg of the active ingredient: cis 4-[l-(3-phosphonoprop~1-eny1)]- piperidine-2-carboxylic acid 5-0 g lactose 212.0 g starch 80-0 g magnesium stearate 3.0 g Procedure: Each powder is passed through a sieve with openings of 0.6 ami. Than the active compound is placed in a mixer and mixed first with the magnesium stearate, then with the lactose and starch until a homogeneous mass is obtained. B?o. 2 hard gelatin capsules are each filled with 300 mg of the prepared mixture.
Capsules containing 1-50 rag of one of the other compounds disclosed hereinbefore are prepared in an analogous manner»
Claims (32)
1. Compounds of formula I, Hse—A—|—OR' 1 1 } OR in which Het is a 2-RJ-pyrro1idiny1, 2-Ri-2,5-dihvdro-pyrrolyl, 2-Ri-1,2,3,6-tetrahydropyridiny1, 2-Ri-1,2,5,6-tetrahydropyridiny1, 2-Ri-piper idiny1 , 2-Ri-tetrahydro-quinolinyl, 2-R*-perhydroquino 1iny1, 2-Ri-2,3-dihydro-indolyl or 2-Ri-perhydroindolyl group which also may be N-substituted by Ci -Ct a 1ky1, pheny1~Ci-C^a Iky 1 , C2-C?aIkoxycarbonvI. benzyloxycarbonyl or by Cz-Cya 1kanoy1 and/or C-substituted in the heterocyclic 5- or 6-ring by Cj—Chalky1 or by pheny1-Ci-C*alky 1 and/or, in the fused benzo or cyclohexano radical that may be present, by Cx-Chalky!s C! -C<, a 1 koxy e halogen or by trif1uoromethy1, Ri is carboxy. C| -C«, alkoxvcarbony 1 , carbamoyl or N-mono- or N,N-di-Ci-Cfea Iky1carbamoyI , A is C2-C4a 1keny1ene and R and R* are each independently hydrogen, Cn-C$alkylf benzyle benzyl substituted in the phenyl moiety by halogen, by C 3 -C
2. Compounds according to claim 1 of formula II s F—OR' ./ K U (ll) a3-r 1 N^/' and compounds of formula II with a double bond present between C-3 and C-4 or between C-4 and C-5 of the piperidinyl ring, wherein R and R' are each iudependent1y hydrogen, Ct -C
3. Compounds of formula II according to claim 2, wherein R and R' are each independently hydrogen, C1-C4alkyl, benzyl, C2-C7a 1kanoy1oxymethyI, or Co-C7 a 1kenoy1oxymet hy1 substituted in the oxymethyl moiety by C3-C4alkyl, by cyclohejcvl or by eye lopenty 1 „ Ri is carboxy „ carbamoyl or C«-C$© 1koxycarbony1; R2 and R3 are hydrogen or C1 -C4©!ky16 and A is alkenylene having from 2 to 4 carbon atoms; and pharmaceutical^ acceptable salts thereof. 4 „ Compounds of formula II according to claim 2, wherein R and R* are each independently hydrogen , Cj-C7a 1kanoy1-oxymethyl or C2 —C7alkanoyloxymethy1 substituted in the oxymethyl moiety by Cj™C
4. 7
5. Compounds according to claim 4 of formula III a 1—oh ' OH / \ I (III) T v wherein A is 1.3-propeny1ene, preferably with the double bond adjacent to the phosphono group, and Ri is carboxy or Cj—alkoxycarbonyI; and pharmaceutica11y acceptable salts thereof.
6. [1-(3~Phosphonoprop-2-eny1)]-piper idine-2-carboxy1i c acid according to claim 1 and pharmaceuticaIly acceptable salts thereof.
7. 4-[1-(3-Phosphonoprop-1-env1)]-piperidine-2-carboxylic ecid according to claim 1 and pharmaceutica11y acceptable salts thereof.
8. Compounds according to claim 1 of formula IV or perhydro derivatives thereof, wherein R and R' are each independently hydrogen- Cj~C*a 1ky1. benzyl, benzyl substituted in the phenyl moiety by halogen, by Ci-C^alkvl or by C* -C«, a 1 koxy, C3 -C7 a 1 kanoy 1 oxyme t hy 1 , or C?-C7alkanoyloxymethy1 substituted in the oxymethyl moiety bv Ct -Ca, a 1 ky 1 or by C3 -Cq eye I oa Iky 1 , R* is carboxy. Ci-C^a 1koxycarbony1, carbamoyl or N-mono- or N,N'-di-Cj-C
9. Compounds according to claim 8 of formula V ^ j—OH e ® Aw jf \/ \ i ij I \ /" (V) " T * or perhydroquino1ine derivatives thereor, wherein A is 1 s 3-propenj/lene with the double bond adjacent to the phosphono group, and Hi is carboxy or C1 -C« a 1koxycarbony 1; and pharmaceutically acceptable salts of said compounds having a salt-forming functional group.
10. Compounds according to claim 1 of formula VI OR' Y'v L l? and the compounds of formula ¥1 with a double bond present between C-3 and C-4 of the pyrrolidinyl ring, wherein R and B' are each independently hydrogen, Ci-C^alkyls benzyl, benzyl substituted in the phenyl moiety by halogen,, by Cj-C&alkyl or by C* -C4 & 1 koxy, C2-C7-a1kanoy1oxymethyl , or Ci -C7a 1kanoy1oxymethy1 substituted in the oxymethyl moiety by Ct-C^alkyl or by C3-Cqeye 1o-alkyls RS is carboxy, Cj -C*5 a 1 koxycarbony 1 , carbamoyl or W-mono- or N,N-di-Cia 1kyIcarbamoy1, R- is hydrogen, Cj-ChalkylB C3 -C7 a 1koxycarbony1, benzv1oxycarbony1 or C^■ C7a 1kanoy1e R3 is hydrogen. Cj-C^alkyl or erv1~C\-C ^ a!ky1„ and h is C;»-C&aIkeny1ene; and salts thereof. ft o
11. Compounds of formula VI according to claim 10, wherein the phosphono-bearing group is attached at the 3-position; R and R' are hydrogen, Ri is carboxy or Ci- C/» a 1 koxycarbony 1 , R2 and R3 are hydrogen, and A is 1,3-propenylene with the double bond adjacent to rht phosphono group; and pharmaceutica1ly acceptable salts thereof.
12. trans-3-[I-(4-Phosphonobu t-3-eny1)]-pyrrolidine-2-carboxylic acid according to claim 1 and pharmaceutica1ly acceptable salts thereof.
13. trans-3-[1-(4-Phosphonobut-2-eny1)]-pyrro1idine-2-carboxwlie ecid according to claim 1 and pharmaceutica1ly acceptable salts thereof.
14. The compounds mentioned in claims I to 13 for use in a method for the therapeutic treatment of the human or animal body.
15. Pharmaceutical preparations containing © compound according to any one of claims 1 to 14 together with a pharmaceutically suitable carrier.
16. The compounds mentioned in claims 1 to 14 as NMDA-antagonists.
17. The use of the compounds mentioned in claims 1 to 14 for the manufacture of pharmaceutica1 preparations.
18. The use of the compounds mentioned in claims 1 to 14 for the manufacture of pharmaceutical preparations for use as NMDA-antagonists.
19. Compounds according to claim 5B selected from the group consisting of ci_s-4-[ 1-( 3~phosphonoprop-2-eny 1 ) ]-piper idine-2-carboxyl 5. c acid, tra.ns-4 - [ 1 - ( 3-phosphono-prop-2-eny1)]-piperidine-2-carboxy1ic acid, cis-fe-f1~(3-phosphonoprop-1 -eny1)]-p iperidine-2-carboxy1ic acid and trans- 4 - [ JL- ( 3-phosphonoprop-JL-eny 1 )]-piperidine-2-carboxy1ic acid, and pharmaceutic©11v acceptable salts thereof.
20. Compounds according to claim 10, selected from cis-3-[i - (4-phosphonobut-3-enyI)]-pyrrol idine-2-carboxy Ii c acid and pharmaceutica11y acceptable salts thereof.
21. Pharmaceutical preparations containing a compound according to claim 19 or 20 together with a pharmaceuti-cally suitable carrier.
22. The compounds mentioned in claims 19 and 20 for use in a method for the therapeutic treatment of the human or animaI body.
23. The compounds mentioned in claims 19 and 20 as NMDA-antagoni sts„
24. „ The us® of the compounds mentioned in claims 19 and 20 for the manufacture of pharmaceutica 1 preparations.
25. The use of the compounds mentioned in claims 19 and 20 for the manufacture of pharmaceutical preparations for use as NMDA-antagonists.
26. A process for the manufacture of compounds according to claim 1 of formula 1 in which all of the symbols have the meanings given in claim 1, and salts thereof, which comprises a) condensifsg an aldehyde or ketone of formula VII Het-A' (VII ) wherein Het and R1 are as defined for formula I but Ri and amino groups are in protected form, and A' is C]-C3alkyl substituted by oxo and containing one carbon atom less than the alkenvlene group AB with a tetraester derivative of methylenediphosphonic acid under basic conditions and, if required, removing protecting groups from the resulting product to obtain a compound of formula I wherein the double bond within group A is directly adjacent to the phosphono group; or b) condensing a compound of formula VIII Het-A-X (VIII) wherein Het, A and R* are as defined for formula I and X is reactive esterified hydroxy,, with a compound capable of introducing the phosphonic acid moiety and having one of the formulae IX and X | H—f—OR" (IX) P(R"") 3 (X) OR" wherein B" is Ci~C*alkyl and R'" is halogen or Ci~ C^elkoxy and, if required v converting the resulting phosphonic acid derivative to the phosphonic acid or another ester derivative thereof: or c) converting to R* a substituent other than R« at position 2 of the heterocyclic ring in a compound otherwise identical to a compound of the invention; and carrying out the said processes with, if necessary, temporary protection of any interfering reactive groups, and then freeing the resulting cosnpound of the invention: if desired converting a resulting compound of the invention into another compound o£ the invention and/or, if desired, converting a resulting free compound into a salt or a resulting salt into the free compound or into another salt; and/or separating a mixture of isomers or of racernates into the individual isomers or raceniates; and/or, if desired, resolving a racemate into the optical ant ipodes .
27. 21. A process according to claim 26, which comprises converting a compound of formula I in which Het is N-substituted by Ci-C7 a 1kanoy1 or by C%-C7a 1koxycarbony1 , R and R' are Ci-C^alkyl, benzyl, benzyl substituted in the phenyl moiety by halogen, by Ci-C*alkyl or by C1-Ci,-alkoxy, Ci -C7 a 1 kanoy 1 oxymethy 1 , or Co -C7 a 1 kanoy 1 oxymethy 1 substituted in the oxymethyl moiety by Cj-C^alkyl or by C3-C3cvc1oa 1 ky 1 „ and Ri is Cj ~C<, a 1 koxycarbony 1 , carbamoyl or N-mono- or N , N-di-Ci-C4a Iky1carbonyl, into a corresponding N-unsubsrituted compound of formula I in which R and R' are hydrogen and R1 is carbosy, by treatment with an inorganic acid or with aqueous alkalis.
28. A process according to claisn 269 which comprises converting a compound of formula I in which Het is N-subst .i tuted by C2 -C7 a 1 kanoy 1 or by Co-C7a 1koxycarbony1 , R and R* are Ci-C*alkyl and RJ is C1-C4a1koxycarbony1, into a corresponding N-unsubstituted compound of formula I in which R and R' ©re hydrogen and R* is carboxy, by treatment with en inorganic acid or with aqueous alkalis.
29. A compound according to claim 1, substantially as hereinbefore described and exemplified.
30. h process for the manufacture of a compound according to claim 1, substantially as hereinbefore described and exemplified.
31. A compound according to claim 1, whenever manufactured by process claimed in a preceding claim.
32. A pharmaceutical preparation according to claim 15, substantially as hereinbefore described and exemplified. F-.R. KELLY A CO.f AGEHTS FOR THE APPLICANTS„
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US93370286A | 1986-11-21 | 1986-11-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
IE873149L true IE873149L (en) | 1988-05-21 |
IE60534B1 IE60534B1 (en) | 1994-07-27 |
Family
ID=25464377
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IE314987A IE60534B1 (en) | 1986-11-21 | 1987-11-20 | Unsaturated phosphonic acids and derivatives |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP0275820B1 (en) |
JP (1) | JPH0686470B2 (en) |
KR (1) | KR880006195A (en) |
AT (1) | ATE60776T1 (en) |
AU (1) | AU610841B2 (en) |
CA (1) | CA1312608C (en) |
DD (1) | DD273837A5 (en) |
DE (1) | DE3768000D1 (en) |
DK (1) | DK609487A (en) |
ES (1) | ES2031927T3 (en) |
FI (1) | FI86638C (en) |
GR (1) | GR3001443T3 (en) |
HU (1) | HU199857B (en) |
IE (1) | IE60534B1 (en) |
IL (1) | IL84492A0 (en) |
MX (1) | MX9437A (en) |
NO (1) | NO170853C (en) |
NZ (1) | NZ222607A (en) |
PH (1) | PH25465A (en) |
PT (1) | PT86168B (en) |
ZA (1) | ZA878699B (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4968678A (en) * | 1988-02-19 | 1990-11-06 | Eli Lilly And Company | Tetrazole excitatory amino acid receptor antagonists |
CA2000901A1 (en) * | 1988-10-21 | 1990-04-21 | Alexis A. Cordi | Phosphono-hydroisoquinoline compounds useful in reducing neurotoxic injury |
US4902695A (en) * | 1989-02-13 | 1990-02-20 | Eli Lilly And Company | Excitatory amino acid receptor antagonists |
EP0424179A3 (en) * | 1989-10-20 | 1991-12-27 | John William Olney | Use of combined excitatory amino acid and cholinergic antagonists to prevent neurological deterioration |
US5238958A (en) * | 1990-02-26 | 1993-08-24 | Warner-Lambert Company | Substituted α-amino acids having selected acidic moieties for use as excitatory amino acid antagonists in pharmaceuticals |
US5194430A (en) * | 1990-05-17 | 1993-03-16 | Merrell Dow Pharmaceuticals Inc. | Heterocyclic-nmda antagonists |
SE9003652D0 (en) * | 1990-11-15 | 1990-11-15 | Astra Ab | NEW HETEROCYCLIC COMPOUNDS |
US5260286A (en) * | 1992-10-16 | 1993-11-09 | Japan Tobacco, Inc. | 2-piperidinecarboxylic acid derivatives useful as NMDA receptor antagonists |
WO1998056788A1 (en) | 1997-06-12 | 1998-12-17 | Rhone-Poulenc Rorer Limited | Imidazolyl-cyclic acetals |
EP3427729A1 (en) | 2017-07-13 | 2019-01-16 | Paris Sciences et Lettres - Quartier Latin | Probenecid for use in treating epileptic diseases, disorders or conditions |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2104079B (en) * | 1981-08-14 | 1985-08-21 | London Polytech | New aminoacid isomers, their production and their medicinal use |
PH23848A (en) * | 1985-05-24 | 1989-11-23 | Ciba Geigy Ag | Certain phosphonic acids and derivatives |
-
1987
- 1987-11-16 AT AT87810662T patent/ATE60776T1/en active
- 1987-11-16 IL IL84492A patent/IL84492A0/en unknown
- 1987-11-16 ES ES198787810662T patent/ES2031927T3/en not_active Expired - Lifetime
- 1987-11-16 EP EP87810662A patent/EP0275820B1/en not_active Expired - Lifetime
- 1987-11-16 DE DE8787810662T patent/DE3768000D1/en not_active Expired - Lifetime
- 1987-11-18 FI FI875097A patent/FI86638C/en not_active IP Right Cessation
- 1987-11-18 PH PH36083A patent/PH25465A/en unknown
- 1987-11-19 PT PT86168A patent/PT86168B/en not_active IP Right Cessation
- 1987-11-19 NZ NZ222607A patent/NZ222607A/en unknown
- 1987-11-19 CA CA000552204A patent/CA1312608C/en not_active Expired - Fee Related
- 1987-11-19 DD DD87309215A patent/DD273837A5/en not_active IP Right Cessation
- 1987-11-20 NO NO874854A patent/NO170853C/en unknown
- 1987-11-20 AU AU81455/87A patent/AU610841B2/en not_active Ceased
- 1987-11-20 KR KR870013064A patent/KR880006195A/en not_active Application Discontinuation
- 1987-11-20 JP JP62292195A patent/JPH0686470B2/en not_active Expired - Lifetime
- 1987-11-20 IE IE314987A patent/IE60534B1/en not_active IP Right Cessation
- 1987-11-20 DK DK609487A patent/DK609487A/en not_active Application Discontinuation
- 1987-11-20 ZA ZA878699A patent/ZA878699B/en unknown
- 1987-11-20 HU HU875161A patent/HU199857B/en not_active IP Right Cessation
- 1987-11-23 MX MX943787A patent/MX9437A/en unknown
-
1991
- 1991-02-07 GR GR90401113T patent/GR3001443T3/en unknown
Also Published As
Publication number | Publication date |
---|---|
NO874854L (en) | 1988-05-24 |
DD273837A5 (en) | 1989-11-29 |
NO170853C (en) | 1992-12-16 |
ATE60776T1 (en) | 1991-02-15 |
JPH01135791A (en) | 1989-05-29 |
IE60534B1 (en) | 1994-07-27 |
PT86168A (en) | 1987-12-01 |
PT86168B (en) | 1990-08-31 |
DE3768000D1 (en) | 1991-03-14 |
EP0275820A2 (en) | 1988-07-27 |
HUT46331A (en) | 1988-10-28 |
AU8145587A (en) | 1988-05-26 |
MX9437A (en) | 1994-01-31 |
EP0275820B1 (en) | 1991-02-06 |
NO170853B (en) | 1992-09-07 |
NO874854D0 (en) | 1987-11-20 |
ZA878699B (en) | 1988-05-23 |
GR3001443T3 (en) | 1992-09-25 |
DK609487A (en) | 1988-05-22 |
PH25465A (en) | 1991-07-01 |
KR880006195A (en) | 1988-07-22 |
EP0275820A3 (en) | 1988-08-03 |
JPH0686470B2 (en) | 1994-11-02 |
DK609487D0 (en) | 1987-11-20 |
FI875097A0 (en) | 1987-11-18 |
ES2031927T3 (en) | 1993-01-01 |
FI86638C (en) | 1992-09-25 |
AU610841B2 (en) | 1991-05-30 |
IL84492A0 (en) | 1988-04-29 |
FI86638B (en) | 1992-06-15 |
CA1312608C (en) | 1993-01-12 |
FI875097A (en) | 1988-05-22 |
HU199857B (en) | 1990-03-28 |
NZ222607A (en) | 1990-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69020262T2 (en) | Azabicyclo-quinoline carboxylic acids. | |
US4746653A (en) | Certain hetero phosphonic acid derivatives of 2-piperidine or 2-tetrahydropyridinecarboxylates and esters thereof which are useful for the treatment of disorders responsive to blockade of the NMDA receptor in mammals | |
EP0658545B1 (en) | Decahydro-isoquinoline derivatives | |
DK167811B1 (en) | PHOSPHONIC ACIDS AND DERIVATIVES THEREOF, PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS, THEIR USE FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS AND PROCEDURES FOR THE PREPARATION OF THE COMPOUNDS | |
DE2935772A1 (en) | DIHYDROPYRIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL AGENTS CONTAINING THE SAME | |
CS240954B2 (en) | Preparation method of 1,2-dihydropyridines | |
DE4221583A1 (en) | SUBSTITUTED BIPHENYLPYRIDONE | |
JPH06329652A (en) | Benzofuranyl- and thiophenyl-alkanecarboxylic acid derivatives | |
JP2005534713A (en) | Dihydropyrazolopyridine compounds | |
EP0273190A1 (en) | Diphosphoric acid derivatives, process for their preparation and pharmaceuticals containing them | |
IE873149L (en) | Unsaturated phosphonic acids | |
EP0330353B1 (en) | Tetrazole excitatory amino acid receptor antagonists | |
US4906621A (en) | Certain 2-carboxypiperidyl-alkylene phosphonic acids and esters thereof useful for the treatment of disorders responsive to N-methyl-D-aspartate receptor blockade | |
US5217963A (en) | Certain phosphonic acid quinoline-2-carboxylic acids, esters or amides useful for treatment of disorders responsive to N-methyl D-aspartate receptor blockade | |
EP0212340B1 (en) | 2-(heteroalkyl)-1,4-dihydropyridines, process for their preparations and pharmaceutical compositions containing them | |
US5565474A (en) | 1-heteroarylazetidines and -pyrrolidines process for their preparation and pharmaceutical compositions containing them | |
US5057506A (en) | Certain phosphonic acids and derivatives useful for the treatment of disorders responsive to N-methyl-D-aspartate receptor blockade | |
US5391763A (en) | 3-aza-bicyclo[3.1.0]hexanes which are intermediates for anti-bacterial azabicyclo quinolone carboxylic acids | |
IE70437B1 (en) | Heterocyclic-NMDA antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Patent lapsed |